Using nucleic acid molecules to identify a disease-related biomarker for immunohistochemistry
Nucleic acid-based testing addresses the limitations of IHC by identifying a wider panel of disease-related genes, enhancing the selection of effective cancer treatments and reducing the risks of ineffective therapies.
Patent Information
- Application Number
- PCT/US2026/028260
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-15
- Filing Date
- 2026-05-14
- Publication Date
- 2026-11-19
AI Technical Summary
Current immunohistochemistry (IHC) methods are limited by the finite amount of tissue in biopsies, restricting the detection of biomarkers for immunotherapies, making it difficult to select effective treatments for cancer, which can lead to ineffective therapies causing emotional hardship and financial burden.
Nucleic acid-based testing is used to identify nucleic acid molecules associated with protein-based biomarkers, enabling a wider panel of disease-related genes to be detected, guiding the selection of therapies predicted to effectively treat conditions by identifying biomarkers likely to be detected in stained samples.
Enhances the ability to identify therapies likely to be effective by nucleic acid-based testing, reducing the risk of ineffective treatments and their associated side effects and costs.
Smart Images

Figure US2026028260_19112026_PF_FP_ABST
Abstract
Description
FMI Docket No.: 0255-WO / 0206-CD L&H Docket No.: F171-6038PCT USING NUCLEIC ACID MOLECULES TO IDENTIFY A DISEASE-RELATED BIOMARKER FOR IMMUNOHISTOCHEMISTRYCROSS-REFERENCE TO RELATED APPLICATION
[0001] This application claims priority to U.S. Provisional App. No. 63 / 806,468, which was filed on May 15, 2025, and is incorporated by reference herein in its entirety.BACKGROUND
[0002] Many individuals rely on immunohistochemistry (IHC) to identify characteristics of a malignant tumor in order to identify potentially successful treatments IHC enables visualization of the presence, location, and abundance of biomarkers directly within tumor samples by using antibodies that specifically bind to proteins expressed in tissue. This technique not only aids in confirming a cancer diagnosis but also plays a critical role in identifying the tumor's origin, classification of cancer subtypes, assessment of tumor grade, and evaluation of biomarkers to guide prognosis and treatment decisions. For example, in breast cancer, the expression of estrogen receptor (ER), progesterone receptor (PR), and HER2 is routinely assessed by IHC to inform therapeutic strategies. As precision medicine continues to advance, IHC remains the standard-of-care in identifying biomarkers to inform both diagnostic clarity and targeted treatment pathways.BRIEF DESCRIPTION OF THE DRAWINGS
[0003] Various aspects of the disclosed methods, devices, and systems are set forth with particularity in the appended claims. A better understanding of the features and advantages of the disclosed methods, devices, and systems will be obtained by reference to the following detailed description of illustrative embodiments and the accompanying drawings, of which:
[0004] FIG. 1 illustrates an example environment for predicting an effective therapy for a health-related condition of a subject using a nucleic acid-based analysis to infer the expression one or more proteins-of-interest.
[0005] FIG. 2 illustrates an example environment for training and utilizing a predictive model to identify one or more proteins-of-interest associated with a therapy predicted to effectively treat a health-related condition.
[0006] FIG. 3 illustrates an example of training data utilized to train one or more ML models.
[0007] FIG. 4 illustrates an example report summarizing predicted categories of a cancer of a subject.
[0008] FIG. 5 illustrates an example environment for sequencing various nucleic acid molecules.
[0009] FIG. 6 illustrates an example process for identifying a therapy predicted to effectively treat a health-related condition of a subject based on identifying one or more proteins-of-interest in a nucleic acid-based analysis.
[0010] FIG. 7 illustrates one or more devices configured to perform various operations described herein.DETAILED DESCRIPTION
[0011] Various implementations of the present disclosure relate to techniques for identifying a biomarker (e.g., a protein-of-interest) related to a health-related condition, such as cancer. In various cases, nucleic acid molecules (e.g., RNA molecules) are obtained from a subject. Sequence read data is generated by sequencing the nucleic acid molecules. The sequence read data is analyzed to identify one or more biomarkers (e.g., one or more protein biomarkers) related to theFMI Docket No.: 0255-WO / 0206-CD L&H Docket No.: F171-6038PCT health-related condition. In various cases, protein data is generated by identifying the presence of the one or more biomarkers in a sample of the subject. The protein data and / or the sequence read data may be analyzed to identify a therapy predicted to effectively treat the health-related condition of the subject.
[0012] In various implementations, these techniques are used to determine whether the health-related condition would be effectively treated by a particular therapy. In particular examples, the particular therapy is targeted to the biomarker. For instance, the therapy may include an antibody-drug conjugate, wherein the antibody is configured to bind to the biomarker. In examples in which the subject has cancer, these techniques are used to determine whether a tumor of the subject is susceptible to a particular treatment. In various cases, various types of health-related conditions can be predicted using various techniques described herein. For example, conditions related to the cancer of the subject can also be determined, such as a type and / or a subtype of the cancer (e.g., a genotypic subtype, a phenotypic subtype, etc.), a predicted stage of the pathogenic condition, or a predicted grade of the pathogenic condition.
[0013] Implementations of the present disclosure provide significant improvements to the technical field of cancer diagnosis, management, and treatment. Using current technologies, a patient’s tumor is typically categorized by performing a tissue biopsy on a potential tumor and performing immunohistological staining and additional analysis on the tissue biopsy sample. The immunohistological stain enables the identification of the presence (or absence) or a biomarker in the tissue biopsy sample. However, the finite amount of tissue in a biopsy restricts the number of biomarkers that can be detected. As the number of immunotherapies, such as antibody-drug conjugates, increases, it may be difficult to determine which biomarkers to select for IHC. Nucleic acid-based testing can identify the presence of nucleic acid molecules associated with protein-based biomarkers related to various therapies (e.g., immunotherapies). Nucleic acid-based testing can identify a wider panel of disease-related genes than direct protein detection due to, for instance, the relative ease by which nucleic acid molecules can be amplified. Accordingly, performing a preliminary nucleic acid-based test can greatly enhance the ability to identify a therapy predicted to effectively treat a condition by identifying biomarkers that are likely to be detected in a stained sample. Accordingly, a clinician relying on various predictions described herein is more likely to identify a treatment that will be effective. Ineffective treatments can cause significant emotional hardship, side effects, and financial burden on the patient, and can be avoided using various techniques described herein.
[0014] Various analyses described herein cannot be performed in the human mind, or by pen and paper. For example, the sequence read data may represent numerous (e.g., thousands) of bases to be analyzed. In various cases, it would be impossible to manually or mentally identify relevant features based on sequence read data. For instance, it would not be possible to attribute features that are relevant to classification of a particular health-related condition or a therapy predicted to effectively treat the condition. Particular implementations of the present disclosure are fundamentally tied to computer technology, and do not represent mere automation of processes that are performed manually.Example Definitions
[0015] As used herein, the terms “deoxyribonucleic acid,” “DNA,” “DNA molecule,” and their equivalents, may refer to a polymer of nucleotides (also referred to as “nucleobases”) containing deoxyribose. The nucleotides in DNA include cytosine (C), guanine (G), adenine (A), and thymine (T). Each DNA nucleotide includes a deoxyribose and a phosphate group. AnFMI Docket No.: 0255-WO / 0206-CD L&H Docket No.: F171-6038PCT example single-stranded DNA (ssDNA) molecule includes a chain of covalently bonded DNA nucleotides. In the example ssDNA molecule, the phosphate group of the mth nucleotide is covalently bonded to the deoxyribose of the (m-1)th nucleotide, wherein m is a positive integer greater than 2 and less than or equal to the number of DNA nucleotides in the chain. In various examples, DNA is double-stranded and includes two ssDNA molecules that are complementary to one another and coiled around each other in a double helix form. The nucleotides of one ssDNA molecule are hydrogen bonded to the nucleotides of the other ssDNA molecule. In particular, the purine adenine (A) hydrogen bonds to the pyrimidine thymine (T), and the purine guanine (G) hydrogen bonds to the pyrimidine cytosine (C).
[0016] As used herein, the terms "ribonucleic acid,” “RNA,” “RNA molecule,” and their equivalents, may refer to a polymer of nucleotides containing ribose. The nucleotides in RNA include cytosine (C), guanine (G), adenine (A), and uracil (U). Each RNA nucleotide includes a ribose and a phosphate group. In an example RNA molecule, the phosphate group of the nth nucleotide is covalently bonded to the ribose of the (n-1 )th nucleotide, wherein n is a positive integer greater than 2 and less than or equal to the number of RNA nucleotides in the chain. Messenger RNA (mRNA) is a type of RNA molecule that is synthesized (or “transcribed”) by RNA polymerase (an enzyme) to be complementary to a gene encoded in a DNA sequence, and is also used by a ribosome to synthesize a polypeptide or protein. An mRNA is therefore an example of a “coding RNA.” In various cases, intron sequences are removed from an mRNA via a process known as “RNA splicing.” MicroRNA (“miRNA”) are single-stranded RNA molecules that perform post-transcriptional gene expression regulation. For instance, a miRNA may bind to a complementary mRNA molecule, thereby cleaving, destabilizing, or otherwise preventing the mRNA molecule from being translated into a polypeptide or protein by a ribosome. In various examples, a miRNA has a length in a range of 21 to 23 RNA nucleotides. As used herein, the terms “non-coding RNA” may refer to a type of RNA that is not translated into a protein. Examples of non-coding RNA include miRNA, transfer RNA (tRNA), and ribosomal RNA (rRNA). The term “functional RNA,” and its equivalents, may refer to any RNA molecule that impacts a biological process. For instance, functional RNA may include mRNA, miRNA, tRNA, rRNA, and the like.
[0017] As used herein, the term “base,” and its equivalents, may refer to a monomer of a polymer. For example, a base of DNA or RNA is a nucleotide.
[0018] As used herein, the term “base pair,” and its equivalents, may refer to a pair of complementary DNA nucleotides, which are hydrogen-bonded to one another in a double-stranded DNA molecule. For example, a base pair includes a first base in a first ssDNA and a second base in a second ssDNA, wherein the first and second bases are complementary and hydrogen-bonded to one another.
[0019] As used herein, the terms “nucleotide,” “nucleobase,” “nucleic acid,” “nucleic acid molecule," and their equivalents, may refer to an organic molecule that includes a nitrogenous base, a sugar, and a phosphate group. In various cases, a nucleotide is a monomer of DNA or RNA. A nucleotide, for instance, is a chemical structure.
[0020] As used herein, the terms “3’ end,” “3-prime end,” and their equivalents, may refer to a terminus of a singlestranded nucleotide polymer that includes a base whose third carbon in its deoxyribose or ribose is bound to a hydroxyl group while being unbound to another base.FMI Docket No.: 0255-WO / 0206-CD L&H Docket No.: F171-6038PCT
[0021] As used herein, the terms “5’ end,” “5-prime end,” and their equivalents, may refer to a terminus of a singlestranded nucleotide polymer that includes a base whose fifth carbon in its deoxyribose or ribose ring is unbound to another base In some cases, the fifth carbon is bound to a phosphate group.
[0022] As used herein, the “length” of a polymer refers to a number of covalently bonded monomers that are included in the polymer. For instance, the length of a DNA molecule may be the number of covalently bonded nucleotides in at least one strand of the DNA molecule and / or the number of base pairs in the DNA molecule. In various examples, the length of an RNA molecule may be the number of covalently bonded nucleotides in the RNA molecule.
[0023] As used herein, the term “gene,” and its equivalents, refers to a sequence of DNA nucleotides that is transcribed into a functional RNA. The functional RNA, for instance, is RNA that is translated into a polypeptide or protein (e.g. , mRNA) or that has some other biological function (e.g., miRNA, tRNA, etc.). A gene is “expressed” when it is used as a template to generate a functional RNA. A subject, for instance, has numerous genes contained in the subject’s genome. A gene may include both introns and exons. As used herein, the term “intron,” and its equivalents, may refer to a subset of DNA nucleotides in a gene that is not used to code for any functional RNA that is expressed by the organism. As used herein, the term “exon,” and its equivalents, may refer to a subset of DNA nucleotides in a gene that is used to code for a functional RNA. For instance, an exon may encode a polypeptide or protein that is expressed by the organism. In various examples, a gene can be represented in data (e.g., as data representative of the sequence of DNA nucleotides in the gene) or as a chemical structure (e.g., as the sequence of DNA nucleotides itself).
[0024] As used herein, the terms “true expression,” “protein expression,” and its equivalents, refer to the protein expression of one or more genes. As used herein, the term “genomic information,” and its equivalents refers to DNA-related information associated with a gene, such as a copy number state, mutations present in DNA (e.g., variants), epigenetic context, regulatory elements (e.g., the presence or absence thereof), genotype (e.g., heterozygous or homozygous), or the like.
[0025] As used herein, the term “genome,” and its equivalents, refers to the aggregate of genes of a subject. In various cases, a genome represents the sequences of several linear DNA molecules that are present in a subject's chromosomes. A “reference genome” refers to an aggregation of genes of one or more reference subjects. In various cases, a genome is represented in data.
[0026] As used herein, the terms “pangenome,” “pan-genome,” “supragenome,” and their equivalents, refers to an aggregate set of genes from multiple subgroups (e.g., strains) within a population (e.g., a clade) of subjects. A pangenome, for example, indicates genes that are present in all subjects within the population, as well as genes that are present in some of the subjects of the population. A pangenome is represented in data, for instance.
[0027] As used herein, the term “transcriptome,” and its equivalents, refers to the aggregate of RNA sequences of a subject. In some cases, a transcriptome is limited to mRNA sequences. In various examples, a transcriptome is represented in data.
[0028] As used herein, the term “genomic DNA,” “gDNA,” “chromosomal DNA,” and their equivalents, may refer to DNA molecules that are obtained from a chromosome and / or nucleus of a cell.FMI Docket No.: 0255-WO / 0206-CD L&H Docket No.: F171-6038PCT
[0029] As used herein, the terms “DNA fragment,” “fragment,” and their equivalents, may refer to DNA molecules that are excised and / or broken off from a larger DNA molecule.
[0030] As used herein, the terms “cell-free DNA,” “cfDNA,” and their equivalents, may refer to DNA fragments that are non-encapsulated and obtained outside of cells within a sample (e.g., a liquid biopsy sample).
[0031] As used herein, the terms “circulating tumor DNA,” “ctDNA,” and their equivalents, may refer to a cfDNA molecule that originates from a cancer cell.
[0032] As used herein, the terms “end motif,” “terminal sequences,” and their equivalents, may refer to a sequence of nucleotides extending from a 3’ or 5’ end of a DNA or RNA molecule. In various cases, the end motif is shorter than a length of the DNA or RNA molecule. For example, the end motif may have a length in a range of 5 to 30 bases or base pairs, a range of 3 to 30 bases or base pairs, or a range of 1 to 30 base pairs.
[0033] As used herein, the term “promoter,” and its equivalents, may refer to a portion of a DNA molecule that binds one or more proteins in order to initiate transcription of a gene. For example, the promotor is located “upstream" of the gene. For example, the promotor is located between the 5’ end of the DNA molecule and the gene. A promotor may include one or more binding sites for RNA polymerase, and / or one or more transcription factor binding sites. In some examples, a promotor includes one or more CpG islands. A promoter, for instance, includes a transcription start site.
[0034] As used herein, the terms “CpG island,” “CGI,” “CpG site,” and their equivalents, may refer to a continuous portion of a DNA molecule whose sequence includes greater than a threshold amount (e.g., greater than 50%) of G-C base pairs.
[0035] As used herein, the term “enhancer,” and its equivalents, may refer to a portion of a DNA molecule that binds one or more proteins in order to increase the chance that a gene will be transcribed. For instance, an enhancer includes one or more transcription factor binding sites. In various cases, an enhancer includes one or more CpG islands.
[0036] As used herein, the term “cancer,” and its equivalents, may refer to a condition of a subject in which particular cells (referred to as “cancer cells”) divide uncontrollably in the subject's body. In some cases, a cancer is characterized by a location or tissue type from which the cancer cells originated. In some examples, a cancer is characterized by a location or tissue type in which the cancer cells are located.
[0037] As used herein, the terms “tumor,” “neoplasm,” and their equivalents, may refer to a mass of tissue including cancer cells.
[0038] As used herein, the terms “tissue of origin,” “tissue origin,” and their equivalents, refers to a differentiated type of tissue from which cancer cells in the body of a subject began dividing uncontrollably in the subject's body.
[0039] As used herein, the terms “liquid biopsy,” “fluid biopsy,” and their equivalents, may refer to a process of obtaining a fluid sample from a subject’s body. The sample, for instance, can be referred to as a “liquid biopsy sample." Examples of fluids that are sampled from the body include blood, plasma, cerebrospinal fluid, sputum, stool, urine, lymphatic fluid, and saliva.
[0040] As used herein, the term “tissue biopsy,” and its equivalents, may refer to a process of obtaining a sample of cells from a subject's body. A tissue biopsy, in various cases, is performed by cutting a mass of cells from the subject's body. For instance, a tissue biopsy is a procedure performed by a surgeon, interventional radiologist, interventional cardiologist,FMI Docket No.: 0255-WO / 0206-CD L&H Docket No.: F171-6038PCT or other specialized clinician. The term “tissue” or “tissue biopsy sample” can be used to refer to the sample of cells obtained using a tissue biopsy.
[0041] As used herein, the term “subject,” and its equivalents, may refer to a human or non-human animal. A subject that is receiving care from at least one care provider may be referred to as a “patient.”
[0042] As used herein, the terms “machine learning,” “ML,” “computer learning,” “artificial intelligence,” and their equivalents, may refer to the use of a computing devices to learn patterns in training data. The process of learning these patterns may be referred to as “training.” In particular cases, one or more computing devices may perform machine learning by executing a machine learning model. As used herein, the terms “machine learning model,” “ML model,” and their equivalents, may refer to data encoding instructions that, when executed by at least one computing device, causes the at least one computing device to learn patterns in training data by optimizing one or more metrics, values, or other types of parameters. After training, an ML model, when executed by at least one computing device, causes the at least one computing device to utilize the optimized parameters in order to perform one or more tasks.
[0043] As used herein, the term “variant,” and its equivalents, may refer to a difference between a subject genetic sequence and a reference sequence. For instance, a variant may correspond to a difference between one or more nucleotides in a genome of a subject and one or more corresponding nucleotides in at least one reference genome or pangenome. A variant may be characterized by its identity (e.g., what nucleotides are different), its position (e.g., where are the nucleotides located in the genome, what chromosome contains the nucleotides, what gene contains the nucleotides, etc.), its length (e.g., how many nucleotides are differentfrom the reference sequence), its type (e.g., substitution, insertion, deletion, copy number alternation, rearrangement of fusion, etc.), and other features that indicates its significance and / or relevance. In some cases, a variant represents any apparent alteration in a sequence that has been read from a nucleic acid molecule with respect to the reference sequence, such as reads cleaved by restriction enzymes (RE). In various examples, a variant can be represented in data (e.g., by data characterizing the variant) or as a chemical structure (e.g., the nucleotides themselves). As used herein, the term “mutation,” and its equivalents, may refer to a change in a gene.
[0044] As used herein, the term “substitution,” and its equivalents, can refer to a nucleotide in a subject sequence that is different than an equivalent nucleotide (e.g., a nucleotide at the same position) in a reference sequence.
[0045] As used herein, the term “insertion,” and its equivalents, can refer to a nucleotide in a subject sequence that is added with respect to a reference sequence.
[0046] As used herein, the term “deletion,” and its equivalents, can refer to the removal of a nucleotide from a nucleotide sequence.
[0047] As used herein, the terms “copy number alternation,” “CNA," “copy number variation,” “CNV,” and their equivalents, can refer to a portion of a reference sequence that is repeated.
[0048] As used herein, the terms “rearrangement of fusion,” “fusion rearrangement,” “translocation,” and their equivalents, can refer to a change in the relative position of one or more portions of a reference sequence, thereby generating a gene that was not present in the reference sequence.FMI Docket No.: 0255-WO / 0206-CD L&H Docket No.: F171-6038PCT
[0049] As used herein, the term “sequencing,’’ and its equivalents, may refer to a process of identifying the order and identity of monomers in a polymer chain, such as the order and identity of nucleotides in a DNA or RNA molecule. The terms “whole genome sequencing,” “WGS,” and their equivalents, may refer to the process of sequencing an entire genome of a subject, including the introns and exons of the genes of the subject. The term “whole exome sequencing,” and its equivalents, may refer to the process of sequencing all exomes of a subject. The term “targeted sequencing,” and its equivalents, may refer to the process of sequencing a portion of the genome of a subject, such as sequencing a single gene of the subject. Various techniques can be utilized to sequence a DNA or RNA molecule, such as massively parallel sequencing (MPS), nanopore sequencing, direct sequencing, Sanger sequencing, or next-generation sequencing (NGS). In various cases, sequencing is performed on physical molecules (e.g., RNA or DNA) and is used to generate data.
[0050] As used herein, the terms “massive parallel sequencing,” “massively parallel sequencing,” “MPS,” and their equivalents, may refer to a technique for simultaneously performing multiple reactions that can be used to identify the order and identity of monomers in multiple polymer chains. In particular cases, massive parallel sequencing can be performed using sequencing-by-synthesis on clonally amplified DNA molecules that are located in spatially separated regions, which are individually monitored by sensors.
[0051] As used herein, the term “nanopore sequencing,” and its equivalents, may refer to a technique for identifying the order and identity of monomers in a polymer chain by transporting the polymer chain from a first space to a second space, wherein the first space and the second space are separated by a substrate, by directing the polymer chain through a small hole (known as a “nanopore”) embedded in the substrate, and monitoring a relative electrical signal (e.g., a voltage or current) between the first space and the second space.
[0052] As used herein, the term “sensor,” and its equivalents, may refer to a physical device or other apparatus that is configured to detect one or more detection signals.
[0053] As used herein, the term “detection signal,” and its equivalents, may refer to a physical signal that can be identified, characterized, or otherwise perceived by a sensor.
[0054] As used herein, the term “sequence read data," and its equivalents, may refer to data that is indicative of an order and identity of monomers in a polymer, such as the order and identity of nucleotides in a DNA or RNA sequence. In various implementations, sequence read data is generated via a sequencing operation.
[0055] As used herein, the term “image,” and its equivalents, may refer to 2D or 3D array of data indicative of an array of pixels or voxels.
[0056] As used herein, the term “ligating,” and its equivalents, may refer to a process of joining two molecules together, for example, with a chemical bond.
[0057] As used herein, the term “adapter,” and its equivalents, may refer to an oligonucleotide that can be ligated to a target nucleic acid molecule. In various cases, an adapter prepares the target nucleic acid molecule for sequencing.
[0058] As used herein, the term “bait molecule,” and its equivalents, may refer to a nucleic acid molecule having a region that is complementary to a region of a target molecule (e.g., cfDNA). A bait molecule includes, for instance, a nucleic acid molecule that can hybridize to ( / .e., is complementary to) a target molecule can be used to capture the target molecule. InFMI Docket No.: 0255-WO / 0206-CD L&H Docket No.: F171-6038PCT some instances, the bait molecule is a capture oligonucleotide (or capture probe). In some instances, the bait molecule is suitable for solution phase hybridization to the target molecule. In some instances, the bait molecule is suitable for solid phase hybridization to the target molecule. In some instances, the bait molecule is suitable for both solution-phase and solid-phase hybridization to the target molecule. The design and construction of bait molecules is described in more detail in, e.g., International Patent Application Publication No. WO 2020 / 236941.
[0059] As used herein, the term “amplifying," and its equivalents, may refer to a process of generating copies of a target molecule, such as a nucleic acid molecule.
[0060] As used herein, the term “hybridization," and its equivalents, may refer to a process by which to complementary single-stranded nucleic acid molecules bind to one another, thereby forming a double-stranded nucleic acid molecule. In certain examples, the double-stranded nature of the nucleic acid molecule is maintained under stringent hybridization conditions. Exemplary stringent hybridization conditions include an overnight incubation at 42 °C in a solution including 50% formamide, 5XSSC (750 mM NaCI, 75 mM trisodium citrate), 50 mM sodium phosphate (pH 7.6), 5XDenhardt's solution, 10% dextran sulfate, and 20 pig / ml denatured, sheared salmon sperm DNA, followed by washing the filters in 0.1XSSC at 50 °C.
[0061] As used herein, the term “complementary,” and its equivalents, may refer to a state of two single-stranded nucleic acid molecules with respective sequences that cause the nucleic acid molecules to spontaneously hybridize to one another. One nucleic acid molecule, for instance, may have a sequence that causes each nucleic acid to hydrogen bond to a respective nucleic acid in the other nucleic acid molecule.
[0062] As used herein, the terms “therapy,” “treatment,” and their equivalents, may refer to a composition or process that can be used to remediate a health problem. Cancer therapies, for instance, include surgery, radiotherapy, chemotherapy, immunotherapy, cell-based therapies, and the like. Examples of cancer therapies include abemaciclib (Verzenio), abiraterone acetate (Zytiga), acalabrutinib (Calquence), ado-trastuzumab emtansine (Kadcyla), afatinib dimaleate (Gilotrif), aldesleukin (Proleukin), alectinib (Alecensa), alemtuzumab (Campath), alitretinoin (Panretin), alpelisib (Piqray), amivantamab-vmjw (Rybrevant), anastrozole (Arimidex), apalutamide (Erleada), asciminib hydrochloride (Scemblix), atezolizumab (Tecentriq), avapritinib (Ayvakit), avelumab (Bavencio), axicabtagene ciloleucel (Yescarta), axitinib (Inlyta), belantamab mafodotin-blmf (Blenrep), belimumab (Benlysta), belinostat (Beleodaq), belzutifan (Welireg), bevacizumab (Avastin), bexarotene (Targretin), binimetinib (Mektovi), blinatumomab (Blincyto), bortezomib (Velcade), bosutinib (Bosulif), brentuximab vedotin (Adcetris), brexucabtagene autoleucel (Tecartus), brigatinib (Alunbrig), cabazitaxel (Jevtana), cabozantinib (Cabometyx), cabozantinib (Cabometyx, Cometriq), canakinumab (Haris), capmatinib hydrochloride (Tabrecta), carfilzomib (Kyprolis), cemiplimab-rwlc (Libtayo), ceritinib (LDK378 / Zykadia), cetuximab (Erbitux), cobimetinib (Cotellic), copanlisib hydrochloride (Aliqopa), crizotinib (Xalkori), dabrafenib (Tafinlar), dacomitinib (Vizimpro), daratumumab (Darzalex), daratumumab and hyaluronidase-fihj (Darzalex Faspro), darolutamide (Nubeqa), dasatinib (Sprycel), denileukin diftitox (Ontak), denosumab (Xgeva), dinutuximab (Unituxin), dostarlimab-gxly (Jemperli), durvalumab (Imfinzi), duvelisib (Copiktra), elotuzumab (Empliciti), enasidenib mesylate (Idhifa), encorafenib (Braftovi), enfortumab vedotin-ejfv (Padcev), entrectinib (Rozlytrek), enzalutamide (Xtandi), erdafitinib (Balversa), erlotinib (Tarceva), everolimusFMI Docket No.: 0255-WO / 0206-CD L&H Docket No.: F171-6038PCT (Afinitor), exemestane (Aromasin), fam-trastuzumab deruxtecan-nxki (Enhertu), fedratinib hydrochloride (Inrebic), fulvestrant (Faslodex), gefitinib (Iressa), gemtuzumab ozogamicin (Mylotarg), gilteritinib (Xospata), glasdegib maleate (Daurismo), hyaluronidase-zzxf (Phesgo), ibrutinib (Imbruvica), ibritumomab tiuxetan (Zevalin), idecabtagene vicleucel (Abecma), idelalisib (Zydelig), imatinib mesylate (Gleevec), infigratinib phosphate (Truseltiq), inotuzumab ozogamicin (Besponsa), iobenguane 1131 (Azedra), ipilimumab (Yervoy), isatuximab-irfc (Sarclisa), ivosidenib (Tibsovo), ixazomib citrate (Ninlaro), lanreotide acetate (Somatuline Depot), lapatinib (Tykerb), larotrectinib sulfate (Vitrakvi), Lenvatinib mesylate (Lenvima), letrozole (Femara), lisocabtagene maraleucel (Breyanzi), loncastuximab tesirine-lpyl (Zynlonta), lorlatinib (Lorbrena), lutetium Lu 177-dotatate (Lutathera), margetuximabcmkb (Margenza), midostaurin (Rydapt), mobocertinib succinate (Exkivity), mogamulizumab-kpkc (Poteligeo), moxetumomab pasudotox-tdfk (Lumoxiti), naxitamab-gqgk (Danyelza), necitumumab (Portrazza), neratinib maleate (Nerlynx), nilotinib (Tasigna), niraparib tosylate monohydrate (Zejula), nivolumab (Opdivo), obinutuzumab (Gazyva), ofatumumab (Arzerra), olaparib (Lynparza), olaratumab (Lartruvo), osimertinib (Tagrisso), palbociclib (Ibrance), panitumumab (Vectibix), panobinostat (Farydak), pazopanib (Votrient), pembrolizumab (Keytruda), pemigatinib (Pemazyre), pertuzumab (Perjeta), pexidartinib hydrochloride (Turalio), polatuzumab vedotin-piiq (Polivy), ponatinib hydrochloride (lolusig), pralatrexate (Folotyn), pralsetinib (Gavreto), radium 223 dichloride (Xofigo), ramucirumab (Cyramza), regorafenib (Stivarga), ribociclib (Kisqali), ripretinib (Qinlock), rituximab (Rituxan), rituximab and hyaluronidase human (Rituxan Hycela), romidepsin (Istodax), rucaparib camsylate (Rubraca), ruxolitinib phosphate (Jakafi), sacituzumab govitecanhziy (Trodelvy), seliciclib, selinexor (Xpovio), selpercatinib (Retevmo), selumetinib sulfate (Koselugo), siltuximab (Sylvant), sipuleucel-T (Provenge), sirolimus protein-bound particles (Fyarro), sonidegib (Odomzo), sorafenib (Nexavar), sotorasib (Lumakras), sunitinib (Sutent), tafasitamab-cxix (Monjuvi), tagraxofusp-erzs (Elzonris), talazoparib tosylate (Talzenna), tamoxifen (Nolvadex), tazemetostat hydrobromide (Tazverik), tebentafusp-tebn (Kimmtrak), temsirolimus (Torisel), tepotinib hydrochloride (Tepmetko), tisagenlecleucel (Kymriah), tisotumab vedotin-tftv (Tivdak), tocilizumab (Actemra), tofacitinib (Xeljanz), tositumomab (Bexxar), trametinib (Mekinist), trastuzumab (Herceptin), tretinoin (Vesanoid), tivozanib hydrochloride (Fotivda), toremifene (Fareston), tucatinib (Tukysa), umbralisib tosylate (Ukoniq), vandetanib (Caprelsa), vemurafenib (Zelboraf), venetoclax (Venclexta), vismodegib (Erivedge), vorinostat (Zolinza), zanubrutinib (Brukinsa), ziv-aflibercept (Zaltrap), and combinations thereof. Examples of cancer therapies also include targeted antibody-based therapies (antibody-drug conjugates, antibody-radioisotope conjugates, and targeted immune cell therapies (e.g., immune effector cells genetically modified to express a chimeric antigen receptor (CAR).
[0063] As used herein, the term "treatment-responsive,” and its equivalents, may refer to a type of cancer cells that can be substantially killed using a predetermined type of therapy. For example, cancer cells of a subject may be responsive to a particular treatment if, after the subject is administered the treatment, the cancer cells are diminished by a particular progression level (e.g., radiographic progression level, marker-based progression level, such as prostate-specific antigen (PSA) progression, etc.). Accordingly, the responsiveness of the cells to the type of therapy may indicate the effectiveness of that therapy.FMI Docket No.: 0255-WO / 0206-CD L&H Docket No.: F171-6038PCT
[0064] As used herein, the term “treatment-resistant,” and its equivalents, may refer to a type of cancer that cannot be substantially killed using a predetermined type of therapy.
[0065] As used herein, the term “metastasis profile,” and its equivalents, may refer to a propensity of a type of cancer to metastasize into one or more differentiated tumor types besides the cancer’s tissue origin. In some implementations, the metastasis profile can further indicate the type of tissue in which the cancer can or is likely to metastasize.
[0066] As used herein, the term “clinical trial,” and its equivalents, may refer to a research study used to evaluate a hypothesis based on participation by one or more subjects. In various examples, a clinical trial can be used to assess the efficacy and / or safety of a proposed therapy. A clinical trial may be performed in furtherance of approval of a treatment by a regulatory authority (e.g., the United States Food & Drug Administration (FDA)).Description of Example Implementations
[0067] Various implementations of the present disclosure will now be described with reference to the accompanying Figures.
[0068] FIG. 1 illustrates an example environment 100 for predicting an effective treatment for a health-related condition of a subject 102 using a nucleic acid-based analysis to infer the expression of one or more proteins-of-interest. In some cases, the subject 102 may have one or more types of cancer and may present to a clinical environment for a disease assessment, such as an assessment of the progression of the cancer(s) and / or an assessment of the health of the subject 102. The subject 102 may present to the environment 100 with a lesion 104.
[0069] According to various examples, the subject 102 has one or more types of cancer, such as adrenal cancer, bladder cancer, blood cancer, bone cancer, brain cancer, breast cancer, carcinoma, cervical cancer, colon cancer, colorectal cancer, corpus uterine cancer, ear, nose and throat (ENT) cancer, endometrial cancer, esophageal cancer, gastrointestinal cancer, head and neck cancer, Hodgkin's disease, intestinal cancer, kidney cancer, larynx cancer, leukemia, liver cancer, lymph node cancer, lymphoma, lung cancer, melanoma, mesothelioma, myeloma, nasopharynx cancer, a neuroblastoma, non-Hodgkin's lymphoma, oral cancer, ovarian cancer, pancreatic cancer, penile cancer, pharynx cancer, prostate cancer, rectal cancer, sarcoma, seminoma, skin cancer, stomach cancer, a teratoma, testicular cancer, thyroid cancer, uterine cancer, vaginal cancer, a vascular tumor, or combinations or metastases thereof. In various implementations, the subject 102 has a solid tumor or a hematologic malignancy.
[0070] In some embodiments, the subject 102 has B cell cancer (multiple myeloma), a melanoma, breast cancer, lung cancer, bronchus cancer, colorectal cancer, prostate cancer, pancreatic cancer, stomach cancer, ovarian cancer, urinary bladder cancer, brain cancer, central nervous system cancer, peripheral nervous system cancer, esophageal cancer, cervical cancer, uterine cancer, endometrial cancer, cancer of an oral cavity, cancer of a pharynx, liver cancer, kidney cancer, testicular cancer, biliary tract cancer, small bowel cancer, appendix cancer, salivary gland cancer, thyroid gland cancer, adrenal gland cancer, osteosarcoma, chondrosarcoma, a cancer of hematological tissue, an adenocarcinoma, an inflammatory myofibroblastic tumor, a gastrointestinal stromal tumor (GIST), colon cancer, multiple myeloma (MM), myelodysplastic syndrome (MDS), myeloproliferative disorder (MPD), acute lymphocytic leukemia (ALL), acute myelocytic leukemia (AML), chronic myelocytic leukemia (CML), chronic lymphocytic leukemia (CLL), polycythemia Vera, HodgkinFMI Docket No.: 0255-WO / 0206-CD L&H Docket No.: F171-6038PCT lymphoma, non-Hodgkin lymphoma (NHL), soft-tissue sarcoma, fibrosarcoma, myxosarcoma, liposarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms' tumor, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, meningioma, neuroblastoma, retinoblastoma, follicular lymphoma, diffuse large B-cell lymphoma, mantle cell lymphoma, hepatocellular carcinoma, thyroid cancer, gastric cancer, head and neck cancer, small cell cancer, essential thrombocythemia, agnogenic myeloid metaplasia, hypereosinophilic syndrome, systemic mastocytosis, familiar hypereosinophilia, chronic eosinophilic leukemia, a neuroendocrine cancer, or a carcinoid tumor
[0071] In various cases, one or more care providers 106 (also referred to as “healthcare provider(s)”) is responsible for monitoring and / or treating the subject 102. The care provider(s) 106 may include one or more of a clinician, a surgeon, an anesthesiologist, a pathologist, a laboratory technician, or the like.
[0072] In various cases, one or more treatments exist for one or more subtypes of the health-related condition. For instance, if cells in the lesion 104 express the protein(s)-of-interest, the treatment(s) may be able to specifically target the cells within the lesion 104 of the subject 102. For instance, the treatment(s) may include one or more immunotherapies, such as an antibody-drug conjugate, an immune checkpoint inhibitor, a T-cell receptor (TCR) therapy, a TCR-bispecific molecule (e.g., bispecific T-cell engagers), a personalized cancer vaccine, a targeted therapy, a personalized therapy, a precision medicine therapy, a chimeric antigen receptor T-cell (CAR T-cell) therapy, monoclonal antibodies, a cytokine therapy, an immunomodulator, a natural killer (NK) cell therapy, an antibody-dependent cellular cytotoxicity (ADCC) enhancer, or the like. In various cases, protei n (s)-of-interest include proteins targeted by the immunotherapy. For instance, an immune checkpoint inhibitor may be targeted to a particular checkpoint protein, such as PD-1 , PDL-1 , LAG-3, CTLA-4, TIM-3, A2AR, B7-H3, B7-H4, VISTA, BTLA, TIGIT, CD47, or the like. In particular cases, protein(s)-of-interest include proteins involved in the therapeutic response (e.g., an immune response, a pharmacological response, a hematological response, a physiological response, etc. of the subject 102 in response to the treatment(s)). If the cells in the lesion 104 fail to substantially express one or more of the protei n (s)-of-interest, the treatment(s) may be ineffective. To avoid potential side effects of the treatment(s), as well as their associated costs, without effectively treating a pathological condition of the subject, the care provider(s) 106 may categorize whether the cells in the lesion 104 and / or the subject 102 express the protein(s)-of-interest.
[0073] According to some implementations, the lesion 104 may be initially identified using a noninvasive technique. For example, the lesion 104 may be visualized using an imaging modality, such as ultrasound, x-ray, computed tomography (CT), magnetic resonance imaging (MRI), positron emission tomography (PET), single photon emission CT (SPECT), or any combination thereof. Using the noninvasive technique, the care provider(s) 106 may identify the presence and location of the lesion 104. In various implementations, the care provider(s) 106 are unable to accurately identify the health-relatedFMI Docket No.: 0255-WO / 0206-CD L&H Docket No.: F171-6038PCT condition of the subject 102 based solely on noninvasive diagnostic techniques. For instance, the care provider(s) 106 may be unable to conclusively determine whether the cells of the lesion 104 express the protein(s)-of-interest and whether the subject 102 will respond to a particular treatment based on noninvasive diagnostic techniques.
[0074] In various implementations of the present disclosure, expression of the protein (s)-of-interest can be identified by obtaining a sample 108 from the lesion 104. The sample 108 is, in various cases, obtained by removing cells from the lesion 104. In some examples, the sample 108 is surgically excised from the subject 102. Tissue biopsies, for example, can include endoscopic biopsies, core needle biopsies, fine-needle aspiration, shave biopsies, punch biopsies, incisional biopsies, excisional biopsies, bone marrow biopsies, surgical biopsies, and the like. In various cases, the sample 108 may be frozen or fixed. For instance, the sample 108 may be obtained from the subject 102 and fixed, by the care provider(s) 106, using a fixative (e.g., formalin, paraformaldehyde, ethanol, etc.). In some cases, freezing or fixing the tissue may prevent degradation of the sample 108 between sample collection and sample analysis. In various examples, the sample 108 is analyzed as fresh tissue.
[0075] In various cases, the sample 108 is transported to a location that is remote from the subject 102 for further processing. For example, the sample 108 is removed from the subject 102 in a clinical environment (e.g., a hospital) and is then transported to a remote laboratory for further testing and analysis.
[0076] In various implementations, the sample 108 includes proteins 110. The proteins 110 may include peptides and / or protein fragments. The proteins 110 may be located in cells in the sample 108. In some cases, the proteins 110 are not extracted from the sample 108. In various examples, the proteins 110 are may be extracted from cells in the sample 108 and subsequently isolated from other cellular materials. In various cases, the proteins 110 indicate a full proteome and / or a full peptidome of the sample 108.
[0077] In various cases, the sample 108 includes nucleic acid molecules 112. According to some examples, the nucleic acid molecules 112 include genomic DNA (gDNA). For instance, the nucleic acid molecules 112 include chromosomal DNA that is located in, or extracted from, cells in the sample 108. According to some cases, the DNA is extracted from nuclei and the cells in the sample 108 using mechanical shearing and / or the introduction of a chemical (e.g., a detergent). The DNA may be subsequently isolated from the proteins 110 and other cellular materials. In some implementations, the nucleic acid molecules 112 indicate an entire genome of the subject 102 and / or the lesion 104. In some examples, the nucleic acid molecules 112 indicate a full RNA transcriptome of the subject 102 and / or the lesion 104 Thus, a genome and / or an RNA transcriptome of the subject 102 and / or the lesion 104 can be determined by sequencing the DNA in the nucleic acid molecules 112. In various cases, the nucleic acid molecules 112 indicate a whole exome of the subject 102 and / or the lesion 104.
[0078] In some examples, the nucleic acid molecules 112 include RNA. In some implementations, the nucleic acid molecules 112 include messenger RNA (mRNA), microRNA, non-coding RNA, functional RNA, or any combination thereof. In some examples, the RNA molecules include at least one of transfer RNA (tRNA), ribosomal RNA (rRNA), or non-coding RNA. Examples of non-coding RNA include microRNA (miRNA), small interfering RNA (siRNA), Piwi-interacting RNA (piRNA), small Cajal body-specific RNA (scaRNA), long intergenic non-coding RNA (lincRNA), circular RNA (circRNA),FMI Docket No.: 0255-WO / 0206-CD L&H Docket No.: F171-6038PCT enhancer RNA (eRNA), natural antisense transcripts (NAT), or the like. Various DNA and / or RNA in the nucleic acid molecules 112 may be indicative of proteins expressed in the cells of the subject 102 and / or the lesion 104.
[0079] In various examples, the care provider(s) 106 may identify a treatment predicted to effectively treat the health-related condition of the subject 102 based on inferring the presence of the protein(s)-of-interest associated with the health-related condition in the sample 108. In various examples, the care provider(s) 106 may perform a protein-based test, such as staining of the sample 108 followed by analysis. For instance, the sample 108 may be stained with a histological stain or an immunohistological stain. The staining may enable the care provider(s) 106 to identify the presence, distribution, or level of the protein(s)-of-interest among the proteins 110 in the sample 108. However, due to the finite amount of tissue available, the care provider(s) 106 may only be able to stain for one or a limited number of proteins. The availability of tissue may be further limited in early stage cancers, when the lesion 104 is small, or in cases where the lesion 104 is difficult-to-access. The risk of missing relevant protein(s)-of-interest present in the sample 108 can lead to inaccurate classification as well as delayed or ineffective treatment of the health-related condition. In various example, inaccurate classification and / or delayed treatment could cause significant emotional hardship to the subject 102 and lasting harm to the subject 102, particularly in cases in which the health-related condition is associated with aggressive progression.
[0080] In various implementations of the present disclosure, a preliminary nucleic acid sequencing-based test (referred to herein as a “nucleic acid-based test” or “sequencing-based test”) for detecting the presence and / or amount of the nucleic acid molecules 112 in the sample 108 is performed in order to infer the presence of the protein (s)-of-interest related to the health-related condition. In some examples, the nucleic acid-based test identifies one or more candidate genes that are, for instance, expressed in the sample. Nucleic acid detection can identify a wider panel of disease-related genes than protein detection due to, for instance, the availability of amplification. While nucleic acid detection can be more sensitive than protein detection, in some examples, nucleic acid information (e.g., genomic information and / or RNA expression) associated a gene may not be representative of true expression of the gene. Protein expression may differ from genomic information and RNA expression due to, for instance, epigenetic mechanisms, such as DNA methylation, histone modification, and chromatin structure, or transcription-related mutations present in RNA. In some examples, the nucleic acid-based test is followed by a protein-based test to detect the presence and / or distribution of the protein (s)-of-interest in order to identify the therapy predicted to effectively treat the health-related condition of the subject 102. Accordingly, the care provider(s) 106 may confirm true expression of the protein(s)-of-interest in the lesion 104 more accurately by using the protein-based test.
[0081] In various implementations, the nucleic acid-based test can be performed, at least partially and / or initially, on a liquid biopsy sample. Relying solely on tissue biopsy samples for detecting health-related conditions has limitations. First, it may be dangerous or otherwise impossible to obtain a tissue sample without significant harm to the subject 102. For instance, it may be impossible to obtain tissue samples from sensitive tissues, such as the brain or spinal cord of the subject 102, without severely harming the subject 102. Second, it is unlikely that the single care provider 106 would be trained to perform the tissue biopsy (which would be performed by a surgeon), to administer anesthesia to the subject 102 during the tissue biopsy (which would be performed by an anesthesiologist), and the analysis of the tissue biopsy (which would beFMI Docket No.: 0255-WO / 0206-CD L&H Docket No.: F171-6038PCT performed by a trained pathologist), such that the classification would utilize multiple highly trained care providers. Various implementations described herein may, in some examples, improve accessibility of particular therapies by utilizing noninvasive sample types for the preliminary nucleic acid-based test. In various implementations, the results of the nucleic acid-based test may be analyzed in order to determine whether to obtain a tissue sample from the subject 102. In various examples, the sample 108 includes a liquid biopsy sample and / or a tissue biopsy sample.
[0082] In some cases, the sample 108 is divided into multiple portions. For example, a first portion of the sample 108 is utilized to perform the nucleic acid-based test. In various cases, the second portion of the sample 108 is reserved to perform the protein-based test. In some examples, the nucleic acid-based test and the protein-based test are performed on the same portion of the sample 108.
[0083] In various implementations, a sequencer 114 is configured to generate sequence read data 116 indicating the sequences of the nucleic acid molecules 112. The sequencer 114, for instance, includes one or more devices that are configured to generate the sequence read data 116 by processing at least a portion of the sample 108. For instance, the sequencer 114 may be configured to generate sequence read data 116 by processing a portion of the sample 108. In some cases, the nucleic acid molecules 112 are extracted from a portion of the sample 108. The extraction can be performed by the sequencer 114, by another device, manually (e.g., by a laboratory technician), or any combination thereof. Any appropriate extraction method known to those of ordinary skill in the art can be utilized.
[0084] In various cases, the sequencer 114 is configured to perform one or more processes (e.g., chemical reactions) on the nucleic acid molecules 112 in order to prepare the nucleic acid molecules 112 for sequencing. For instance, the sequencer 114 may ligate adapters onto the nucleic acid molecules 112 and / or amplify the nucleic acid molecules 112, such that numerous copies of the ligated nucleic acid molecules 112 are available for sequencing. Examples of the adapters include, for example, amplification primers, flow cell adapter sequences, substrate adapter sequences, or sample index sequences. The nucleic acid molecules 112 (e.g., the ligated nucleic acid molecules) may be amplified by generating multiple copies of the nucleic acid molecules 112 using one or more techniques such as polymerase chain reaction (PCR), a non-PCR amplification technique, or an isothermal amplification technique.
[0085] The sequencer 114 may identify the length, position, and identity of the bases in the nucleic acid molecules 112 by sequencing the nucleic acid molecules 112 (e.g., the amplified and / or ligated nucleic acid molecules 112). In various implementations, the sequencer 114 utilizes first-generation sequencing (e.g., Sanger sequencing), second-generation sequencing (e.g., massive parallel sequencing), third-generation sequencing (e.g., nanopore sequencing), or a combination thereof. In some cases, the sequencer 114 is configured to sequence substantially all of the nucleotides of all of the nucleic acid molecules 112 fragments obtained from the sample 108. In some examples, the sequencer 114 is configured to perform targeted sequencing. For instance, the sequencer 114 may determine whether the nucleic acid molecules 112 fragments contain one or more predetermined sequences at one or more genomic locations.
[0086] In various cases, the sequencer 114 includes one or more sensors that are configured to detect physical signals (also referred to as "detection signals”) that are indicative of the nucleotide sequences of the nucleic acid molecules 112. The sequencer 114 may perform sequencing-by-synthesis. For example, the sequencer 114 may include one or moreFMI Docket No.: 0255-WO / 0206-CD L&H Docket No.: F171-6038PCT optical sensors configured to detect optical signals emitted from fluorescently tagged nucleotide triphosphates (NTPs) that are joined together in a synthesized DNA strand using the ligated nucleic acid molecules 112 as templates. The optical signals detected by the optical sensor(s), for instance, are indicative of the sequences of the nucleic acid molecules 112. The sequencer 114 may perform nanopore sequencing. In various cases, the sequencer 114 includes one or more electrical sensors configured to measure an electrical signal (e.g., an electrical current) across a substrate as the ligated nucleic acid molecules 112 are directed through a nanopore extending through the substrate. The electrical signal over time, in various cases, is indicative of the sequences of the nucleic acid molecules 112 in the sample 108. The sequencer 114, in various implementations, is configured to generate the sequence read data 116 as digital data based on the analog signals detected by the sensor(s). For instance, the sequencer 114 includes one or more analog to digital converters (ADCs). In various cases, the sequencer 114 includes at least one processor configured to generate the sequence read data 116.
[0087] In some implementations, the sequencer 114 performs RNA sequencing (RNA-seq) on the nucleic acid molecules 112. For example, the nucleic acid molecules 112 include RNA that is extracted from the sample 108. In some examples, the RNA in the nucleic acid molecules 112 is fragmented. In various implementations, complementary DNA (cDNA) is generated using reverse transcriptase, such that the cDNA includes sequences that are complementary to the RNA in the nucleic acid molecules 112 from the sample 108. The cDNA, according to various cases, can be sequenced using the DNA sequencing techniques described above. Accordingly, in some cases, the sequence read data 116 indicates sequences of RNA present in the sample 108, which may be indicative of the transcriptome of the subject 102 and / or the lesion 104.
[0088] In various cases, the sequencer 114 performs sequencing on a subset of the nucleic acid molecules 112. For instance, the sequencer 114 may perform targeted sequencing on one or more predetermined genes. In some examples, the genes include one or more of ALK, AXL, BRAF, CCNE1, CD274, CD3D, CD3E, CD3G, CD8A, CD8B, CD19, CD22, CD25, CD30, CD33, CD37, CD56, CD66b, CD68, CD79B, CD142, CD166, CD276, CEACAM5, CEACAM8, CLDN18, CNNE1, DC-LAMP, DLL3, EGFR, ERBB2, ERBB3, ESR1, F3, FGFR, FGFR2b, FOLR1, FOXP3, GZMB, HAVCR2, IL2RA, IL3RA, MET, MGMT, MKI67, MLH1, MS4A1, MSH2, MSH6, MTAP, MZB1, NaPi2b, NCAM1, NECTIN4, NKp46, PanCK, PDCD1, PMS2, PR, PTEN, PTK7, ROR1, ROR2, RORC, RORA, RORyT, ROS1, SLC39A6, , TACSTD2, TGFB1, TIGIT, TIM3, TNFRSF8, TREM2, or TROP2.
[0089] In various cases, the genes include one or more of A2M, ABCA6, ABCB1 , ABCC2, ABCC9, AB11 , ABL1 , ABL2, ACACA, ACLY, ACRBP, ACSL3, ACSL6, ACTA2, ACTG1, ACTG2, ACTN1, ACTR3B, ACVR1, ACVR1C, ACVRL1, ADAM12, ADAM19, ADAM2, ADCY7, ADGRB1, ADGRB3, ADGRF5, ADGRL4, ADRB2, MLLT10, AFF1, AFF3, AFF4, AFP, AGR2, AGR3, AHR, AIFM3, AKT1 , AKT2, AKT3, ALDH2, ALK, ALOX12, AMZ1, ANGPT1, ANGPT2, ANLN, ANPEP, ANXA1, ANXA2, APC, APCDD1, APEX2, APH1A, APLN, APOBEC3A, APOBEC3B, APOBR, APOL6, APP, APPBP2, AR, AREG, ARF1, ARG2, ARHGAP15, ARHGDIA, ARID1A, ARID1B, ARID3A, ARNT, ARNT2, ASAP2, ASB13, ASCL2, ASGR2, ASTE1, ASXL1, ATAD2, ATIC, ATM, ATP2C1, ATP8A1, ATP8B2, ATR, AURKA, AURKB, AVPR1A, AXIN2, AXL, B2M, B3GNT5, BAALC, BAG1, BAG2, BAGE4, BAK1, BAMBI, BAP1, BASP1, BATF, BATF3, BAX, BAZ2B, BCAM, BCAR1, BCAR3, BCAS1, BCL10, BCL11A, BCL11B, BCL2, BCL2A1, BCL2L1, BCL2L11, BCL3, BCL6, BCL7A, NBEAP1, BCL9, BOOR, BCR, BIN2, BIRC3, BIRC5, BLK, BLM, BLNK, BLVRA, BMF, BMP2, BMP4, BMPR1A, BMPR1B, BNC2,FMI Docket No.: 0255-WO / 0206-CD L&H Docket No.: F171-6038PCT BRAF, BRCA1, BRCA2, BRD3, BRD4, BRDT, BRINP3, BRIP1, BRPF1, BTG1, BTG3, BTK, BTLA, BUB1, BUB1B, C10orf35, EMSY, C15orf48, C1RL, C3, C5, C5AR2, CA4, CAGE1, CALB2, CALML3, CALR, CAMTA1, CANX, CASP1, CASP3, CASP8, CASP9, CBFA2T3, CBFB, CBL, CBLC, CCDC140, CCDC50, CCL11, CCL13, CCL14, CCL17, CCL18, CCL19, CCL2, CCL20, CCL21, CCL3, CCL4, CCL5, CCL8, CCNA2, CCNB1, CCNB2, CCND1, CCND2, CCND3, CCNE1, CCNE2, CCNG2, CCR4, CCR5, CCR7, CCR8, CCRL2, CCSER2, CD14, CD163, CD19, CD1A, CD1B, CD1D, CD1E, CD2, CD209, CD22, CD226, CD244, CD247, CD248, CD27, CD276, CD28, CD33, CD34, CD36, CD38, CD3D, CD3E, CD3G, CD4, CD40, CD40LG, CD44, CD46, CD47, CD5, CD6, CD63, CD68, CD7, CD70, CD74, CD79A, CD79B, CD80, CD81, CD84, CD86, CD8A, CD8B, CD9, CD93, CD96, CDC20, CDC25C, CDC45, CDC6, CDCA3, CDCA5, CDCA7, CDCA7L, CDCA8, CDH1, CDH3, CDH5, CDHR1, CDK2, CDK4, CDK6, CDK8, CDKN1A, CDKN1B, CDKN1C, CDKN2A, CDKN2AIP, CDKN2B, CDKN2B-AS1, CDKN2D, CDKN3, CDT1, CDX2, CEACAM1, CEACAM3, CEACAM5, CEACAM8, CEBPA, CEBPB, CELSR2, CENPA, CENPF, CENPM, CNTRL, CEP55, CES1, CES2, CFD, CHAF1B, CHEK1, CHEK2, CHN1, CHUK, CIC, CIITA, CITED4, CLCA2, CLDN18, CLDN3, CLDN4, CLDN5, CLDN6, CLDN7, CLEC10A, CLEC14A, CLEC4C, CLEC5A, CLEC9A, CLIC2, CLIC4, CLTC, CMKLR1, CMPK2, CNN1, CNTNAP2, COL15A1, COL18A1, COL1A1, COL1A2, COL3A1, COL4A1, COL4A2, COL6A3, COL7A1, COPB2, CPA3, CRAT, CREB1, CREB3L1, CREB3L2, CREBBP, CRKL, CRLF2, CRNDE, CRYAB, CSF1, CSF1R, CSF2, CSF3R, CSMD1, CSNK1E, CSNK1G2, CST7, CT45A1, CT45A2, CT45A3, CT62, CTAG1A, CTAG1B, CTAG2, CTAGE1, CTGF, CTLA4, CTNNB1, CTNNBIP1, CTPS1, CTPS2, CTSV, CTSW, CUX1, CX3CL1, CXCL1, CXCL10, CXCL11, CXCL12, CXCL13, CXCL2, CXCL3, CXCL6, CXCL8, CXCL9, CXCR1, CXCR2, CXCR4, CXCR5, CXCR6, CXXC5, CYB5R2, CYBB, CYLD, CYP4F3, DCAF12, DCLK1, DCN, DDB2, DDIT3, DDIT4, DDR1, DDR2, DDX10, DDX21, DDX4, DDX58, DDX6, DEK, DENND3, DEPTOR, DHH, DHX58, DIDO1, DIRC2, DKK1, DKK2, DKK4, DLC1, DLL3, DLL4, DMBT1, DMD, DNMT1, DNMT3A, DOCK5, DOT1L, DRAM1, DSC2, DSCR8, DTL, DTX1, DTX2, DTX3L, DUSP1, DUSP18, DUSP22, DUSP6, DVL1, TCF3, E2F1, E2F4, E2F5, EBF1, ECSCR, ECT2, EDNRB, EGF, EGER, EGLN3, EGR1, EGR2, EIF4A2, ELF4, ELF5, ELK4, ELL, ELN, EMCN, EME1, EML4, EML6, MLLT1, ENTPD1, EOMES, EP300, EP400, EPCAM, EPHA4, EPHA7, EPOR, EPS15, ERAP1, ERAP2, ERBB2, ERBB3, ERCC1, ERCC2, ERCC3, ERCC4, ERCC5, EREG, ERG, ERN2, ESM1, ESR1, RUNX1T1, ETS1, ETV1, ETV4, ETV5, ETV6, EWSR1, EXO1, EZH2, F11R, FAM101B, AMER1, FAM171B, FAM26F, FAM46A, FAM64A, FANCA, FANCB, FANCC, FANCD2, FAP, FAS, FASN, FAT2, FBXW11, FBXW7, FCAR, FCGR2B, FCGR3B, FCRL2, FCRL5, FEV, FGF9, FGFBP2, FGFR1, CEP43, FGFR2, FGFR3, FGFR4, FGR, FKBP4, FLI1, FLNA, FLT1, FLT3, FLT3LG, FLT4, FMN1, FMN2, FMOD, FN1, FNBP1, FNIP2, FOLH1, FOLR1, FCS, FOSB, FOXA1, FOXC1, FOXM1, FOXO1, FOXO3, FOXO4, FOXO6, FOXP1, FOXP3, FPR1, FPR3, FSTL3, FUCA1, FUS, FUT4, FUT8, FZD1, FZD10, FZD2, FZD5, FZD6, FZD7, GABBR2, GADD45A, GADD45B, GAGE1, GAGE2E, GAGE6, GAGE8, GALNT10, GALNT12, GAS1, GAS7, GBP5, GIMAP5, GIMAP7, GINS2, GJA4, GLI1, GLIS2, GMFG, GMNN, GMPS, GNA12, GNG11, GNLY, GOLM1, GPA33, GPC4, GPC6, GPI, GPR143, GPR146, GPR160, ARHGAP26, GRB7, GREB1, GRM4, GSK3B, GSTA1, GSTM1, GUSB, GZMA, GZMB, GZMH, GZMK, H2AFX, HABP2, HAMP, HAP1, HAVCR2, HBEGF, HCLS1, HCST, HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9, HDC, HELZ2, HERPUD1, HES1, HES2, HES4, HES5, HES6, HEY1, HEY2, HEYL, HGF, HHIP, HIF1A, HIP1, HIST1H1A, H1-4, H2AC11, HIST1H2AI, HIST1H2BL, H3C2,FMI Docket No.: 0255-WO / 0206-CD L&H Docket No.: F171-6038PCT HIST2H2BF, HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DQA1, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-E, HLF, HMGA1, HMGA2, HMGCS2, HMMR, HOPX, HORMAD1, HOXA11, HOXB2, HPCAL1, HRAS, HRASLS, HSD11B1, HSP90AA1, HSP90AB1, HSPA4L, HSPB1, ICAM1 , ICAM2, ICOS, ID1, ID2, IDO1, IFI16, IFI27, IFI35, IFI6, IFIT1, IFIT2, IFIT3, IFITM2, IFITM3, IFNG, IFNL2, IGF1, IGF1R, IGFBP1, IGFBP3, IGFBP4, IGLL5, IHH, IKBKE, IKZF1, IKZF2, IKZF3, IL10, IL11, IL12A, IL13, IL13RA2, IL15, IL16, IL17RA, IL1A, IL1B, IL1R1, IL1RN, IL21R, IL23A, IL2RA, IL3, IL33, IL3RA, IL4R, IL6, IL6R, IL6ST, IL7, IL7R, IMPDH1, INPP1, INSR, INSRR, IPO8, IQGAP3, IRF1, IRF4, IRF7, IRF8, IRGM, IRS2, IRX4, ISG20, ISY1, ITGAM, ITGAV, ITGAX, ITGB1, ITGB2, ITGB4, ITK, ITM2A, ITPKB, JAK1, JAK2, JAK3, JAML, JAZF1, JUN, KCNE3, KCNJ15, KCNK5, KCNMA1, KDM1A, KDM3B, KDM4C, KDM5C, KDM5D, KDR, KDSR, KIAA0040, KIAA0125, KIAA0319L, KIAA1462, KIAA1804, KIF13B, KIF23, KIF2B, KIF2C, KIF5B, KIFC1, KIR2DL1, KIR2DL3, KIR3DL1, KIR3DL2, KIR3DS1, KIT, KLF2, KLF4, KLK3, KLRB1, KLRC3, KLRC4, KLRD1, KLRK1, KMT5A, KRAS, KRT14, KRT17, KRT31, KRT5, KRT6A, KRTCAP3, KYNU, LAG3, LAIR1, LAMB1, LASP1, LATS1, LATS2, LCK, LCN2, LCP1, LDHB, LEF1, LGALS2, LGALS3, LILRB5, LIMD1 , LIMK2, LINC-ROR, LINC00598, LIPH, LIPI, LMNA, LMO1 , LMO2, LMO3, LMO4, LOC100506207, LOC100507346, L00100507424, LPP, LRMP, LRP1, LRP8, LRRC15, LTF, LTK, LUZP4, LY6E, LY6G6D, LYL1, LZTR1, MACC1, MAF, MAFB, MAGEA1, MAGEA10, MAGEA11, MAGEA12, MAGEA2B, MAGEA3, MAGEA4, MAGEA5, MAGEA6, MAGEA8, MAGEA9B, MAGEB1, MAGEB10, MAGEB16, MAGEB17, MAGEB18, MAGEB2, MAGEB3, MAGEB4, MAGEB5, MAGEB6, MAGEC1, MAGEC2, MAGEC3, MALAT1, MALT1, MAML2, MAML3, MAP2, MAP2K1, MAP2K3, MAP3K7, MAP3K8, MAP4K4, MAPK1, MAPK3, MAPKAPK2, MAPT, MARK1, MASP2, MAST1, MAST2, MASTL, MB21D1, MBTD1, MCAM, MCL1, MCM10, MCM2, MCM4, MCM6, MDC1, MDM2, MDS2, MECOM, MEF2C, MEF2D, MEG3, MEGF9, MELK, MEN1, MEST, MET, METRNL, MFAP4, MFAP5, MGA, MGMT, MGST2, MIA, MIAT, MICB, MIR100, MITF, MKI67, MRTFA, MRTFB, MLF1, MLH1, KMT2A, KMT2D, KMT2C, MLPH, MME, MMP11, MN1, MNX1, MOCOS, MPZL3, MRAS, MRE11, MRVI1, MS4A1, MS4A2, MS4A4A, MSH2, MSH6, MSI2, MSMB, MSN, MST1R, MTAP, MTCP1, MTHFD1L, MTOR, MUC1, MUC16, MUTYH, MVP, MX1, MX2, MYB, MYBL2, MYC, MYCL, MYCN, MYCT1, MYD88, MYH11, MYH9, KAT6A, NAB2, NAT1, NAV3, NBEA, NBN, NCAM1, NCOA2, NCOR1, NCR1, NDC80, NDE1, NDRG1, NEAT1, NECTIN1, NECTIN2, NECTIN3, NEK1, NEK2, NEK6, NELL2, NF1, NF2, NFATC2, NFE2L2, NFIC, NFKB2, NID2, NIN, NKD1, NKG7, NKX3-1, NLK, NONO, NOS1, NOS1AP, NOTCH1, NOTCH2, NOTCH3, NOTCH4, NPAS2, NPM1, NR4A3, NRAP, NRARP, NRAS, NRG1, NRG2, NRP1, NRP2, NRTN, NSD1, NT5C3A, NT5E, NTRK1, NTRK2, NTRK3, NUF2, NUMA1, NUMBL, NUP214, NUP98, NUTM1, NUTM2A, NXF2B, NXPH3, OAS3, OASL, ODC1, OGN, OLFM1, OLFM4, OLIG2, ORAI2, ORC6, P2RY8, PADI2, PAFAH1B2, PAGE5, PAK2, PAK4, PALB2, PAMR1, PARP1, PARP12, PARP14, PAX3, PAX5, PAX7, PAX8, PBK, PBX1, PBX3, PCDH17, PCSK1, PDCD1, PDGFA, PDGFB, PDGFD, PDGFRA, PDGFRB, PDIA3, CD274, PDCD1LG2, PDZK1IP1, PECAM1, PFN2, PGR, PHF1, PHF11, PHGDH, PHLPP1, PICALM, PIK3CA, PIK3CD, PIK3CG, PIK3R1, PIK3R2, PIM2, PIM3, PKN1, PLA2G7, PLAC8, PLAG1, PLAGL2, PLCB4, PLEK2, PLEKHA4, PLEKHB1, PLK2, PLPP3, PLVAP, PMEPA1, PML, PMS1, PMS2, PNOC, PNPLA7, PODXL, POLD1, POLE, POU2F2, POU5F1, PPARG, PPM1J, PPP1R13L, PRDM15, PRDM16, PRF1, PRKACA, PRKACB, PRKACG, PRKCA, PRKCB, PRMT1, PRMT5, PRND, PROM1, PRPF6, PRPF8, PSAT1, PSCA, PSD3, PSENEN, PSIP1, PSMB10, PSMB8, PSMB9, PSME1, PTCH1, PTCH2, PTCRA, PTEN, PTGDS, PTGER2,FMI Docket No.: 0255-WO / 0206-CD L&H Docket No.: F171-6038PCT PTGER4, PTGS2, PTPN1, PTPN11, PTPN22, PTPRB, PTPRC, PTPRK, PTPRO, PTPRZ1, PTRF, PTTG1, PUM1, PVR, PVRIG, PXDC1, R3HDM1, RAB23, RAB27A, RAB29, RAC1, RAD50, RAD51, RAD51AP1, RAD51C, RAD51B, RAD51D, RAD52, RAD54L, RAF1, RAPGEFL1, RARA, RASGRF1, RASIP1, RASSF6, RB1, RBL1, RBM24, RBP7, RBX1, RECQL4, REG4, RELA, RERG, RET, RGCC, RGS10, RGS16, RGS2, RHOA, RHOH, RHOJ, RIT1, RNF13, ROBO4, ROCK2, ROPN1, ROPN1B, R0R1, R0R2, RORA, RORC, RORyT, ROS1, RP1, RPL23, RPL39L, RPS26, RPS6KA1, RPS6KB1, RPSAP52, RRAGC, RRAS, RRM2, RSAD2, RSPO2, RSPO3, SNX29, RUNX1, RUNX2, RUNX3, S100A12, S100A8, S1PR2, SAA1, SAGE1, SAMD9L, SAP30, SCD, SCD5, SCML4, SCUBE2, SDC1, SDHA, SDHB, SDHC, SDHD, SEC31A, SELL, SELP, SEMA3E, SEMA4B, SEMA4C, SEMA6D, SEMA7A, SEPT7, SEPT12, SEPTIN5, SEPTIN6, SEPTIN9, SEPW1, SERPINA9, SERPINB13, SERPINB2, SERPINB5, SERPINE1, SERPINF1, SESN1, SESN2, SESN3, SET, SF3B1, SFRP1, SGK3, SH2D1A, SH2D1B, SH2D2A, SH3BP5, SH3GL1, SH3PXD2A, SHCBP1, SHISA5, SHISA8, SHOC2, SIGLEC5, SKP1, SLAMF1, SLC16A3, SLC1A2, SLC22A8, SLC39A6, SLC40A1, SLC45A3, SLC7A8, SLC9A3R1, SLCO2A1, SLFN11, SLIT2, SMAD2, SMAD3, SMAD4, SMAD9, SMARCB1, SMURF2, SNAI1, SNRNP70, SNW1, SOCS1, SOS1, SOS2, SOX11, SOX17, SOX18, SOX9, SP2, SPANXA1, SPANXB1, SPANXC, SPARC, SPARCL1, SPIB, SPINK1, SPN, SPP1, SPRY4, SRC, SRD5A1, SREBF1, SRSF3, SS18, SSPO, SSX1, SSX2, SSX2B, SSX3, SSX4, SSX5, ST3GAL2, STAT1, STAT3, STAT4, STAT6, STAU2, STEAP1, STEAP4, STIL, STK11, STON1, SULF2, SULT1A1, SUV39H2, SYCP1, SYCP3, SYK, TACSTD2, TAF15, TAGAP, TAGLN, TAL1, TAL2, TAP1, TAP2, TAPBP, TBC1D10C, TBC1D4, TBC1D9, TBL1XR1, TBX21, TCF12, TCF4, TCF7L1, TCF7L2, TCL1A, TCL6, TDG, TDGF1, TDRD7, TEAD1, TEC, TEK, TENM3, TERC, TERT, TET1, TET2, TET3, TFCP2L1, TFE3, TFEB, TFF1, TFG, TFPT, TFRC, TGFB1, TGFB2, TGFB3, TGFBI, TGFBR1, TGFBR2, THADA, THBD, THBS1, THY1, TIAM1, TIE1, TIGIT, TIM3, TIMP3, TLL1, TLR2, TLR3, TLX1, TLX3, TMEM173, TMEM38A, TMEM45B, TMEM55B, TMPRSS2, TNF, TNFRSF10C, TNFRSF11A, TNFRSF14, TNFRSF17, TNFRSF1A, TNFRSF1B, TNFRSF8, TNFRSF25, TNFRSF8, TNFRSF9, TNFSF10, TNFSF11, TNFSF12, TNFSF13B, TNFSF4, TNFSF9, TNKS, TNKS2, TNS1, TOP1, TOP2A, TP53, TP53BP1, TP53INP1, TP53INP2, TP63, TP73, TPM1, TPM2, TPM3, TPM4, TPSAB1, TPSB2, TPST1, TPX2, TRAT1, TREM2, TREX1, TRIM2, TRIM24, TRIM56, TRIP11, TROP2, TRPS1, TSC1, TSC2, TSHR, TTC39B, TTK, TTL, TTTY14, TTYH1, TWIST1, TYK2, TYMS, UBA7, UBE2C, UBE2T, UBXN4, UGT8, UNC5B, UPK1A, UPP1, USP44, USP6, USP8, VAV3, VCAM1, VCL, VEGFA, VEGFB, VEGFC, VGLL1, VHL, VIM, VNN3, VPREB1, VWF, WASH5P, WBSCR17, NSD2, NSD3, WIF1, WNT11, WNT16, WNT2, WNT5B, WNT7A, WNT7B, WNT8B, WT1, WWTR1, XCL1, XCL2, XIST, XPA, XPO1, YAP1, YWHAE, YY1, ZAP70, ZBP1, ZBTB16, ZBTB46, ZC3H13, ZC3HAV1, ZEB1, ZEB2, ZIC2, ZMAT3, ZMYM2, ZNF384, ZNF521, ZNF608, ZNF703, ZNF750, orZNRF3. The sequencer 114, in some cases, may refrain from sequencing at least a portion of the nucleic acid molecules 112 that do not correspond to the subset.
[0090] According to various implementations, the sequencer 114 may identify the predetermined genes based on the health-related condition of the subject 102. For instance, in some examples, the predetermined genes include one or more of: ALK, CD274, EGFR, ERBB2, MET, ROS1, or TACSTD2, and the health-related condition includes non-small cell lung cancer (NSCLC). In some examples, the predetermined genes include one or more of: BRAF, ERBB2, MSH6, PMS2, MSH2, or MLH1, and the health-related condition includes colorectal cancer (CRC). In some examples, the predeterminedFMI Docket No.: 0255-WO / 0206-CD L&H Docket No.: F171-6038PCT genes include one or more of: CLDN18, ERBB2, or FGFR2b, and the health-related condition includes gastric cancer. In some examples, the predetermined genes include one or more of: ESR1, PR, ERBB2, or CD274, and the health-related condition includes breast cancer. In some examples, the predetermined genes include one or more of: ERBB2, FOLR1, MSH6, PMS2, MSH2, or MLH1, and the health-related condition includes endometrial cancer.
[0091] In various implementations, a data analyzer 118 is configured to identify the protein(s)-of-interest based on the sequence read data 116. For instance, the data analyzer 118 may determine whether RNA expression of a gene corresponding to a protein-of-interest is above a particular threshold. In some examples, the data analyzer 118 is configured to determine whether the RNA expression of a panel of genes is above a threshold. In various cases, the panel of genes may be associated with the effectiveness of a therapy. The threshold(s) may be determined based clinical guidelines, clinical data (e.g., data obtained from a population of subjects), data obtained from a database, or the like. In various examples, the threshold(s) are determined based on nucleic acid levels of a population of subjects with a particular health-related condition and / or a population of subjects without the particular health-related condition. In some cases, the RNA expression may be normalized. For instance, RNA expression may be normalized with respect to sequencing depth, gene transcript length, tumor purity, variable total mRNA levels across multiple samples, cancer tissue type of origin differential mRNA expression, or biopsy site tissue type differential mRNA expression. In some implementations, RNA expression may be expressed as Transcripts Per Million (TPM) or Fragments Per Kilobase Million (FPKM). In some examples, the data analyzer 118 is configured to analyze genomic information associated with the protein(s)-of-interest, such as a copy number state of a genetic loci associated with a protein-of interest. The data analyzer 118 may identify the protein(s)-of-interest based on identifying the candidate gene(s) from the sequence read data 116
[0092] In various cases, the data analyzer 118 includes a model configured to infer the presence of the protein(s)-of-interest in the sample 108 based on the sequence read data 116. For instance, the data analyzer 118 may include one or more machine learning (ML) models that are pretrained to identify the protein(s)-of-interest. The ML model(s), in some examples, include a logistic regression model, a random forest model, an artificial neural network (ANN), a decision tree, a k-nearest neighbor (KNN) model, a support vector machine (SVM), or a naive Bayes classifier. For example, parameters of the ML model(s) may have been previously optimized based on training data including features of individuals within a population omitting the subject 102. For instance, the ML model(s) was trained using an unsupervised or semi-supervised learning technique, wherein the parameters were optimized to categorize (e.g., cluster) the features of the population. In some cases, the ML model(s) was trained using a supervised learning technique and pre-classified data, wherein the training data further included ground truth preliminary scores of the individuals in the population, such that the parameters were optimized to minimize a loss between predicted preliminary scores generated by the ML model(s) based on the features of the population and the ground truth preliminary scores experienced by the individuals in the population. To increase training robustness, the population represented by the training data may include individuals without the health-related condition, as well as individuals with a variety of types of presentations of the health-related condition. In some examples, the data analyzer 118 may include a regression model, threshold rule, confidence interval, or other type of statistical model capable of categorizing the protein(s)-of-interest based on the sequence read data 116.FMI Docket No.: 0255-WO / 0206-CD L&H Docket No.: F171-6038PCT
[0093] In various implementations, if the nucleic acid-based analysis indicates that there is a significant (e.g., greater than a threshold) likelihood that a protein-of-interest is present in the sample 108, direct protein detection may be performed to confirm the inference. In various cases, a protein detector 120 is configured to detect the presence and / or amount of the proteins 110 in the sample 108 (e.g., the first portion of the sample 108). In various cases, the protein detector 120 is configured to perform one or more processes (e.g., chemical reactions) on the sample 108 to prepare the proteins 110 for detection and / or sequencing. In some cases, the protein detector 120 may apply a capture agent that is configured to bind to a protein-of-interest in the sample 108. Examples of ligands (e.g., capture agents) include antibodies, antibody binding fragments, an aptamer, a peptide, a protein, an enzyme, a tag, a small molecule, a nanobody, or the like. The capture agent, in various cases, may be linked to a detectable label, such as a fluorophore (fluorescein isothiocyanate (FITC), Alexa Fluor dyes, Cy3, Cy5, DAPI), a colorimetric dye (3,3'-Diaminobenzidine (DAB), 3-Amino-9-ethylcarbazole (AEC), Fast Red, 5-Bromo-4-chloro-3-indolyl phosphate / Nitro blue tetrazolium (BCIP / NBT), a quantum dot, a ruthenium-based compound (e.g., tris(bipyridyl)ruthenium(ll) complex (Ru(bpy)32+), an iron-based compound (e.g., iron(lll) tris(phenanthroline)), a luminescent probe (e.g., a luminescent phosphor, a phosphorescent probe, a luciferase-based probe, a bioluminescent probe, a chemiluminescent probe, etc.), a chromogenic product, a visible byproduct, or the like. The protein detector 120 may be configured to detect a signal associated with the detectable label to determine the presence and / or the quantity of the protein-of-interest in the sample. The signal may include a fluorescent signal, a colorimetric signal, an absorbance, a refractive index, radioactivity, an electrochemical signal, an electrochemiluminscent signal, or the like. The presence and / or level of the protein-of-interest can be identified by the protein detector 120 based on an analysis of the signal.
[0094] The protein detector 120, in some cases, includes a photodetector configured to detect an intensity of light emitted by the detectable label. In various examples, the intensity of the light emitted by the detectable label is proportional to the amount of the protein-of-interest in the sample 108. In some instances, the protein detector 120 is configured to determine the amount of the protein-of-interest in the sample 108 based on the intensity of the light detected by the photodetector. Examples of photodetectors include photodiodes, photomultiplier tubes (PMTs), charge-coupled devices (CCDs), or complementary metal-oxide semiconductor (CMOS) sensors). In some cases, the protein detector 120 includes a surface plasmon resonance (SPR) sensor, a quartz crystal microbalance (QCM) sensor, an electrochemical sensor, an optical waveguide sensor, or the like configured to detect the detectable label. In various examples, the protein detector 120 may be configured to image at least a portion of the sample 108 to identify the presence of the protein(s)-of-interest. For example, the protein detector 120 may use fluorescence microscopy to detect a fluorescent probe linked to the capture agent in the sample 108.
[0095] In some examples, an individual (e.g., the subject 102, the care provider(s) 106, etc.) can visually identify the presence of the detectable label. For instance, the protein detector 120 may include a lateral-flow based test. The capture agent may be immobilized on a membrane of the test. In some examples, the individual or the protein detector 120 applies the sample 108 (e.g., a portion of the sample 108) to the test, causing the particular protein to bind to the capture agent. In various cases, the detectable label includes a fluorophore, a nanoparticle, a colorimetric dye, a visible byproduct (e.g.,FMI Docket No.: 0255-WO / 0206-CD L&H Docket No.: F171-6038PCT of an enzymatic reaction), or the like. The individual may be able to visually identify the presence and / or a level (e.g, by evaluating a color intensity) of the detectable label in the test. Based on the interaction between the protein-of-interest and the detectable label, the individual may identify, for instance, a color change corresponding to the presence and / or the level of the protein-of-interest in the sample 108.
[0096] Optionally, the protein detector 120 is configured to sequence the proteins 110 in the sample 108. In some cases, the proteins 110 are extracted from the sample 108. The extraction can be performed by the protein detector 120, by another device, manually (e.g., by a laboratory technician), or any combination thereof. Any appropriate extraction method known to those of ordinary skill in the art can be utilized. The protein detector 120 may digest the proteins 110 using, for instance, an enzyme. In some examples, the protein detector 120 may ionize the digested proteins 110. For example, the protein detector 120 may use electrospray ionization (ESI), matrix assisted laser desorption ionization (MALDI), atmospheric pressure chemical ionization (APCI), chemical ionization (Cl), electron impact (El), or the like to ionize the digested proteins. Based on ionizing the digested proteins 110, the protein detector 120 may determine a mass-to-charge ratio of the digested proteins 110. In various cases, the protein detector 120 may fragment the digested proteins 110, such as by collision-induced dissociation, electron transfer dissociation, or the like. The protein detector 120 may be configured to determine the presence and / or amount of the proteins 110 by analyzing the mass-to-charge ratios of the digested protein and the ions associated with the fragmented proteins. For instance, the protein detector 120 may compare the mass-to-charge ratios of the digested protein and the ions associated with the fragmented proteins 110 to those of known target proteins to determine sequences of the proteins 110 in the sample 108.
[0097] The protein detector 120 may be configured to confirm the presence and / or absence of one or more predetermined target proteins-of-interest in the sample 108. In some examples, the protein detector 120 is configured to detect one or more of: AXL, CCNE1, CD3, CD3D, CD3E, CD3G, CD8, CD8A, CD8B, CD19, CD22, CD33, CD68, CD79B, CD276, CEACAM5, CEACAM8 (i.e, CD66b), CLDN18, DLL3, ERBB2, ERBB3, ESR1 (i.e, ER), FGFR2b, FOLR1, FOXP3, GZMB (i.e, granzyme B), HAVCR2 (i.e., TIM3), IL2RA (i.e., CD25), IL3RA (i.e., CD123), MET (e.g., c-MET Overexpression), MGMT, MKI67 (i.e, Ki-67), MS4A1(i.e, CD20), MTAP, NCAM1 (i.e, CD56), PDCD1 (i.e, PD1), PTEN, ROR1, RORyT**, SLC39A6 (i.e, LIV-1), TACSTD2 (i.e, TROP2), TGFB1, TIGIT, TNFRSF8 (i.e, CD30), TOP1, or TREM2. In some examples, the protein detector 120 is configured to detect one or more of: ACE2, ACP5, ACY1, ADA2, ADAM8, ADGRE2, ADGRE5, ADGRG1, AFP, AGR2, ALCAM, ALK, ALPP, ANG, ANG2, ANGPTL4, anti-p53 antibodies, ANXA10, APEX1, AR, AREG, ARSA, B2M, B4GALT1, BAMBI, BMP6, BST2, BTA, BTN2A1, C19ORF12, CA125, CA12, CA15-3, CA19-9, CA242, CA50, CA72.4, CCL14, CCL15, CCL21, CCL22, CD163, CD200, CD200R1, CD22D, CD27, CD274D, CD28, CD300C, CD302, CD38D, CD48, CD6, CD70, CD74, CD79BD, CD83, CDCP1, CDH2, CDH6, CDHR2, CEA, CEACAM21, CEACAM5, CHI3L1, CLEC14A, CLEC5A, CLSTN2, CNDP1, CNTN5, COL4A1D, CRELD2, CRIM1, CRLF1, CRP, CRTAM, CSF1, CTSD, CTSL, CXADR, CXCL13, CXCL17, CXCL9, CYFRA, DCTPP1, DDR1, DKK3, DPP10, DSC2, EFEMP1, EFNA4, EGFL7, ENG, ENPP2, EPHA2D, EPHB4D, EPS8L2, ERBB2D, ESM1, EZR, FABP1, FCRL1, FCRL2, FCRL3, FCRL5, FCRLB, Ferritin, FGFR2B, FLT3LG, FOLR1, FRZB, FSTL3, FUT3, FUT5, FUT5, GAL, GALNT3, Gastrin 17, GCNT1, GDF15, GDNF, GFAP, GGH, GGT1, Glycodelin, GOLM2, GP2, GRN, HAVCR1, HE4, HLA-E, HYOU1, ICAM3,FMI Docket No.: 0255-WO / 0206-CD L&H Docket No.: F171-6038PCT IDS, IFNGR1I, IFNLR1, IGF-1, IGFBP3, IGFBP6, IGFBP7, IGSF3, IL10RB, IL12A, IL12B, IL12BD, IL12RB1, IL18BP, IL18R1, IL2RAB, IL4RD, IL5RAD, IL6R, IL6STD, ITGA5, ITGB2D, ITGB7D, ITIH3, ITM2A, JAM, JCHAIN, KLRB1, KRT14, KRT18, KRT19, LAG3, LAIR2, LAYN, LGALS9, LILRB1, LRIG1, LRP11, LTA, LTBP2, LY9, LYPD8, MARCO, MDK, MILR1, MMED, MMP12, MMP7D, MMP9, MSLN, MSR1, NBL1, NECTIN4D, NFASC, NOMO1, NOS1, NOS3, Notum, NRCAM, NRP2, NT5E, Osteopontin, PARP1, PCDH17, PCOLCE, PDCD1D, PDGFC, Pepsinogen I, Pepsinogen II, PDGFRAB, PGFD, PIGR, PIK3AP1, PIVKA-II, PLAUR, PLXNB2, PREB, PRELP, proGRP, Prolactin, PRSS8, PSA, PSIP1, PTPRS, PVR, RARRES2, RBP2, RBP5, REG3A, REG4, RNASET2, R0R1, RTN4R, SCC, SDC1, SDC4, SEMA4D, SEMA7A, SERPINA9, SEZ6L2, SFTPA2, SH2D1A, SIGLEC1, SIGLEC10, SIGLEC6, SLAMF1, SLAMF6, SLAMF7D, SLAMF8, SPARCL1, SPINK1, SPINK4, SPINT1, SPON2, SPP1, SRP14, ST6GAL1, STC2, STFR2, SULF2, SULT2A1, TCL1A, TFF1, TFF2, TFPI2, TGFBI, TGFBR2, THBD, TIMP1, TNF, TNFRSF10, TNFRSF10A, TNFRSF10B, TNFRSF11B, TNFRSF13, TNFRSF13B, TNFRSF13C, TNFRSF14, TNFRSF19, TNFRSF1A, TNFRSF1B, TNFRSF21, TNFRSF4, TNFRSF8, TNFRSF9, TNFSF13, TNFSF13BD, TNFSF13BI, TNR, TPP1, TREML2, VCAM1, VTCN1, WAS, or YKL40.
[0098] The protein detector 120 is configured to generate protein data 122 based on the presence and / or amount of the protein(s)-of-interest in the sample 108. In some cases, the protein data 122 may indicate a whole proteome and / or a whole peptidome of at least a portion of the sample 108. In some cases, the protein data 122 may indicate sequences of a subset of the proteins and / or peptides in the sample 108. In various examples, the protein data 122 is indicative of a level of one or more proteins 110 in the sample 108. The level of a protein-of-interest may be indicative of a presence, a concentration, an amount, or another metric associated with the protein-of-interest. In some examples, the level of a protein-of-interest is indicative of a weighted level or a normalized level (e.g., an amount of a particular protein normalized to the total protein in the sample 108) of the protein-of-interest.
[0099] In various implementations, the data analyzer 118 determines one or more input features 124 indicative of a likelihood that a therapy will effectively treat the health-related condition of the subject 102. In some examples, the input features 124 include or are indicative of the protein data 122 and / or the sequence read data 116.
[0100] The input feature(s) 124, in some examples, include a copy number state of one or more genetic loci indicated by the sequence read data 116. In various implementations, a number of copies of a predetermined sequence at a given locus in the genome of the subject 102 (also referred to as a “copy number” of the locus) is determined. The copy number state, in various implementations, may indicate copy numbers of one or more loci in the genome of the subject 102. For instance, the copy number state may indicate the presence and / or amount of copies of various sequences present in the genome of the subject 102, which may be due to copy number variation.
[0101] According to various examples, the sequence read data 116 may represent a genome of the subject 102. Various portions of the sequence read data 116 are aligned with at least one reference sequence (e.g., a reference genome). The aligned data is segmented using at least one segmentation technique (e.g., a circular binary segmentation (CBS) method, a maximum likelihood method, a hidden Markov chain method, a walking Markov method, a Bayesian methods, a long-range correlation method, a change point method, or any combination thereof), thereby generating non-overlapping segments of the sequence read data 116, wherein a sequence associated with a given segment is associated with theFMI Docket No.: 0255-WO / 0206-CD L&H Docket No.: F171-6038PCT same copy number (e.g., a number of instances in which the sequence appears in the segment). Various genetic loci are binned, or otherwise sorted, with respect to the segments of the genome of the subject 102. The copy number state, for instance, is representative of the respective copy numbers associated with the genetic loci. In some cases, the copy number state is dependent on (e.g., assigned based on) a major allele coverage ratio and a minor allele coverage ratio, as well as one or more copy number grid models.
[0102] In various cases, the input feature(s) 124 are derived based on fragments in the nucleic acid molecules 112, and are therefore referred to as ''fragmentomic features.” Examples of fragmentomic features include endpoint positions of the fragments in a reference genome (e.g., right endpoints, left endpoints, etc.), endpoint counts at positions within the reference genome (e.g., right endpoint counts, left endpoint counts, etc.), fragment lengths, end motifs, relative read depths of the fragments, the presence of one or more variants in the fragments, or any combination thereof. Fragmentomic features can be expressed in the spatial domain, in an alternate domain, in a preprocessed form, or any combination thereof.
[0103] In some implementations, the input feature(s) 124 include the presence or absence of a variant (e.g., a pathogenic variant) in one or more genes associated with classifying the health-related condition. In various cases, the genes include one or more of the genes with potential relevance to a determination of whether the subject 102 has a health-related condition, as listed above.
[0104] In some cases, the input feature(s) 124 include additional biomarker data. That is, the input feature(s) 124 may include non-genomic features. For instance, input feature(s) 124 may include data indicating at least one of a histological and / or immunohistological image of the sample 108 or another sample collected from the subject 102, a genomic alteration, or a viral status of the subject 102. The additional biomarker data may be generated based on the sample 108, medical images, or other samples obtained from the subject 102. In some cases, the additional biomarker data includes an image of a stained section of the sample 108 or another sample collected from the subject 102. For instance, the stained section is stained with hematoxylin and eosin (H&E) and / or at least one immunostain. In various examples, the input features(s) 124 includes data indicating the presence of at least one biomarker in another sample collected from the subject 102 (e.g., a blood sample, a urine sample, a saliva sample, etc.). The biomarker may include a nucleic acid, a protein, an enzyme, a metabolite, a hormone, an immunological biomarker, or the like.
[0105] In various examples, the input feature(s) 124 include additional clinical data. For instance, the input feature(s) 24 may include data indicating results of at least one of a physical exam, an imaging procedure (e.g., an ultrasound, an MRI, a CT scan, a PET scan, a colonoscopy, an endoscopy, a mammogram, etc.), an electrophysiological test (e.g., an electrocardiogram, an electroencephalogram), a functional test (e.g., to assess the function of an organ or a system), or another assessment performed on the subject 102. In some cases, the input feature(s) 124 include a family history of the pathological condition of the subject 102, lifestyle factors associated with the health-related condition (e.g., smoking history, environmental exposures, etc.), or demographic information of the subject 102 (e.g., age, gender, body mass index (BMI), etc.).FMI Docket No.: 0255-WO / 0206-CD L&H Docket No.: F171-6038PCT
[0106] To determine whether a therapy would effectively treat the health-related condition of the subject 102, a predictive model 126 is configured to generate one or more therapy indicator(s) 128 based on the input feature(s) 124. The predictive model 126, for example, may include one or more mathematical and / or computer-based models that are configured to predict the therapy indicator(s) 128 based on the input feature(s) 124. For instance, the predictive model 126 may include a regression model, threshold rule, confidence interval, or other type of statistical model capable of categorizing the therapy indicator(s) 128 based on the input feature(s) 124. In various cases, the predictive model 126 includes at least one classifier configured to generate the therapy indicator(s) 128 based on the input feature(s) 124.
[0107] In various implementations, the predictive model 126 includes at least one trained ML model configured to output the therapy indicator(s) 128 in response to receiving the input feature(s) 124 in input data For example, parameters of the ML model(s) may have been previously optimized based on training data including features of individuals within a population omitting the subject 102. For instance, the ML model(s) was trained using an unsupervised or semi-supervised learning technique, wherein the parameters were optimized to categorize (e.g., cluster) the features of the population. In some cases, the ML model(s) was trained using a supervised learning technique and pre-classified data, wherein the training data further included ground truth health-related conditions of the individuals in the population, such that the parameters were optimized to minimize a loss between predicted conditions generated by the ML model(s) based on the features of the population and the ground truth conditions experienced by the individuals in the population. To increase training robustness, the population represented by the training data may include individuals without the health-related condition, as well as individuals with a variety of types of presentations of the health-related condition. Various types of ML models can be included in the predictive model 126, such as a neural network (e.g., a CNN), a nearest-neighbor model, a regression analysis model, a clustering model, a principal component analysis model, a gradient boosting model, a random forest, or any combination thereof. In some cases, the predictive model 126 includes a hybrid model, that includes multiple types of ML models. For instance, the predictive model may include a CNN and a clustering model.
[0108] In various implementations, the therapy indicator(s) 128 are categorized by comparing the input feature(s) 124 of the subject 102 to the clusters in the clustering model. The therapy indicator(s) 128 are determined based on a comparison between the input feature(s) 124 and the clusters in the clustering model. In various cases, a data object defined by the input feature(s) 124 of the subject 102 is defined in the feature space of the clustering model. The clustering model, for instance, may determine that the data object is present within the boundary of a particular cluster that was previously defined based on the training data. In some cases, the clustering model determines that the data object is associated with a particular cluster based on a distance between the data object and the particular cluster in the feature space. In some cases, the distance is at least one of a Euclidian distance, a Manhattan distance, a Hamming distance, a Minkowski distance, a Chebyshev distance, or any combination thereof. For instance, the clustering model determines that the distance between the data object and the boundary and / or a centroid of the particular cluster is below a threshold distance. In some examples, the clustering model classifies the health-related condition (e.g., a condition that is effectively or ineffectively treated by a particular therapy) of the subject 102 into a classification associated with the particular cluster byFMI Docket No.: 0255-WO / 0206-CD L&H Docket No.: F171-6038PCT determining that a distance between at least one data object corresponding to the population features in the cluster is below a threshold distance.
[0109] In various cases, the therapy indicator(s) 128 are generated using the input feature(s) 124 and the predictive model 126. In various cases, the predictive model 126 may determine that the subject 102 is associated with one or more conditions and / or prognostic features associated with the cluster in which the input feature(s) 124 belong. In various implementations, the therapy indicator(s) 128 are indicative of a therapy predicted to effectively treat the lesion 104. For example, the therapy indicator(s) 128 indicate a likelihood that the subject 102 has a cancer type and / or a cancer subtype. The therapy indicator(s) 128 may indicate that the subject 102 has a cancer subtype that is predicted to be effectively treated by a particular therapy. In various implementations, the therapy indicator(s) 128 indicate a likelihood that the subject 102 has a particular health-related condition. For example, the therapy indicator(s) 128 may indicate a dosage of one or more therapeutic agents (e.g., an antibody-drug conjugate, a targeted therapy, etc.) predicted to treat the health-related condition of the subject 102. Various therapies may be specified by the therapy indicator(s) 128. Therapies include an antibody-drug conjugate, an immune checkpoint inhibitor, a T-cell receptor (TCR) therapy, a TCR-bispecific molecule, or a personalized cancer vaccine, a targeted therapy, a personalized therapy, or a precision medicine therapy. In some cases, therapies include drug therapy, a targeted therapy, vaccine therapy, stem cell transplantation, blood transfusion, physical therapy, psychiatric therapy, surgery, a behavior modification program, an interventional procedure, a pain management procedure, a minimally invasive procedure, dialysis, or respiratory support. Drug therapy can include one or more anticancer agents (e.g., chemotherapy, radiation therapy, immunotherapy, a targeted therapy, surgery, etc.) In various cases, the therapy indicator(s) 128 provide a dosage of one or more therapeutic agents predicted to treat the health-related condition and / or its predicted subtype. Various examples of behavior modification programs include, for instance, a nutritional plan (e.g., a particular diet), a physical exercise plan, Cognitive Behavioral Therapy (CBT), or a stress management plan.
[0110] In various implementations, the therapy indicator(s) 128 are indicative of at least one predicted cell type of the lesion 104 of the subject 102 and / or a predicted tumor progression of the lesion 104. In some cases, the predicted tumor progression may indicate a rate of growth of the lesion 104. In some examples, the predicted tumor progression indicates a rate of growth of one or more predicted cell types of the lesion 104. In various cases, the predicted tumor progression indicates a predicted metastasis profile of the subject 102. The predicted metastasis profile may indicate a time (e.g., a date, a time range) when the lesion 104 will metastasize. In some examples, the therapy indicator(s) 128 include a likelihood that the lesion 104 will metastasize (e.g., to the lymph nodes, or to a particular organ) by a given time or an indication that there is greater than a threshold (e.g., 80%) likelihood that the lesion 104 will metastasize by the given time. In various cases, the therapy indicator(s) 128 may indicate a prognosis of the subject 102. The prognosis of the subject 102 may indicate a predicted survivability of the subject 102. In various examples, the therapy indicator(s) 128 include a predicted condition (e.g., disease, cancer type, etc. ) of the subject 102; a predicted disease subtype of the subject 102; a predicted survivability of the subject 102; one or more predicted symptoms of the subject 102; a predicted stage of the predicted disease of the subject 102; a predicted grade of the predicted disease of the subject 102; a predicted activityFMI Docket No.: 0255-WO / 0206-CD L&H Docket No.: F171-6038PCT level of the subject 102 (e.g., a predicted Eastern Cooperative Oncology Group (ECOG) performance status of the subject 102); a predicted body mass index (BMI) of the subject 102; a predicted smoking history of the subject 102; a predicted breast density of the subject 102; a clinical trial that the subject 102 is predicted to qualify (e.g., be eligible) for; a general health of the subject 102; or a characteristic of the predicted disease of the subject. For instance, the therapy indicator(s) 128 may indicate that the subject 102 is likely to qualify for a clinical trial based on an age, a gender, a disease stage, and previous treatments of the subject 102.
[0111] In various examples, the prognostic features may include predicted characteristics of the disease that is experienced by the subject 102, predicted symptoms (e.g., predicted chronic symptoms, such as diabetes, hypertension, etc., or predicted medical events, such as heart attack, stroke, etc.) of the subject 102, predicted causes of the disease, or the like. Accordingly, the health-related condition of the subject 102 can be determined based on the input feature(s) 124.
[0112] In some implementations, the predictive model 126 is unable to conclusively categorize the health-related condition of the subject 102. For example, the predictive model 126 may determine that the input feature(s) 124 of the subject 102 do not fit within any of the previously defined clusters in the clustering model. In various cases, the predictive model 126 may output an indication that that the categorization of the health-related condition is inconclusive. In some implementations, the predictive model 126 may determine that health-related condition of the subject 102 would not be effectively treated by immunotherapy. The predictive model 126, in some cases, may output an indication of one or more follow-up tests to determine whether another type of treatment (e.g., chemotherapy, surgery, etc.) would be more likely to successfully treat the health-related condition.
[0113] A report generator 130 is configured to generate a report 132 based, at least in part, on the therapy indicator(s) 128. The report 132, for example, includes consumable data that can inform the care provider(s) 106 about the predicted condition of the subject 102. In various implementations, the report 132 may indicate the results of additional analyses, such as the results of a histological study, whole transcriptome sequencing, cfRNA sequencing, long-read RNA sequencing, comprehensive genomic profiling, whole exome sequencing (WES), whole genome sequencing (WGS), a hotspot panel test, a DNA methylation test, a DNA fragmentation test, an RNA fragmentation test, a microsatellite instability (MSI) test, or a viral status test. The performance of such tests is within the ordinary skill of the art, with additional detail provided elsewhere herein. The report 132, for example, may include a genomic profile of the subject 102 based on various combinations of the above analyses and tests.
[0114] In some implementations, the report 132 indicates that a follow-up test of the subject 102 is indicated. For instance, in response to determining that the categorization of the health-related condition of the subject 102 is inconclusive, the report generator 130 may generate the report 132 to indicate that one or more additional tests, such as a physical exam, a histological study, or a nucleic acid nucleic acid-based test (e.g., genome sequencing, exome sequencing, additional DNA sequencing, RNA sequencing, transcriptome sequencing, etc.) should be performed in order to accurately identify the health-related condition of the subject 102. In some examples, the one or more additional tests may include diagnostic imaging, such as magnetic resonance imaging, computed tomography scan, ultrasound, X-ray, mammogram, positron emission tomography, bone scintigraphy, myelography, virtual colonoscopy, echocardiography, radiography,FMI Docket No.: 0255-WO / 0206-CD L&H Docket No.: F171-6038PCT nuclear medicine, fluoroscopy, or single-photon emission computed tomography. Various examples of follow-up tests appropriate for autoimmune conditions, for instance, include an electroencephalography (EEG), an electrocardiogram (ECG), Holter monitoring, blood pressure monitoring, plethysmography, a urea breath test, respiratory function testing, blood gas analysis, electromyography (EMG), a nerve conduction study (NCS), ultrasound imaging, endoscopy, or a bone density measurement. In some cases, the follow-up test includes performance of another nucleic acid sequencing test.
[0115] In various cases, the report 132 isoutput to aclinical device 134. For example, the report generator 130 transmits the report 132 to the clinical device 134. In various implementations, the clinical device 134 is a computing device that is operated by, owned by, or otherwise associated with the care provider(s) 106. For instance, the clinical device 134 may be a desktop computer, a laptop computer, a smart phone, or some other computing device associated with the care provider(s) 106. The clinical device 134, in various cases, outputs the report 132 to the care provider(s) 106. In some cases, the clinical device 134 includes a display (e.g., a screen) that visually presents the report 132. In various cases, the clinical device 134 includes a speaker that outputs a sound indicative of the report 132. The clinical device 134, in various cases, may output the information in the report 132 using one or more output mechanisms or devices.
[0116] The care provider(s) 106 may review the report 132 by interacting with the clinical device 134. The report 132, in various cases, may enhance the clinical decision-making of the care provider(s) 106. For instance, the care provider(s) 106 may prepare and / or administer a therapy to the subject 102 based on the report 132. According to various implementations, the care provider(s) 106 may initiate the therapy and / or refer the subject 102 to another care provider to receive the therapy. In various cases, if the predicted condition of the subject 102 is a disease (e.g., respiratory disease), the care provider(s) 106 may prescribe, recommend, or administer an agent in order to treat the disease the subject 102.
[0117] In various implementations, the care provider(s) 106 may develop a diagnosis and / or prognosis of the subject 102 based on the report 132. In various implementations, the care provider(s) 106 may communicate information in the report 132 to the subject 102.
[0118] While FIG. 1 illustrates both sequence read data 116 and protein data 122, implementations of the present disclosure are not so limited. In various examples, the sequence read data 116 can be analyzed in order to determine whether the treatment predicted to effectively treat the health-related condition of the subject 102 can be determined without performing the protein-based analysis. The nucleic acid-based analysis can be performed, in various cases, by performing noninvasive or a minimally invasive procedure (e.g., to obtain a liquid biopsy sample), while the tissue biopsy sample used for the protein-based analysis may be collected by an invasive procedure. A liquid biopsy sample, for instance, includes blood, plasma, cerebrospinal fluid, sputum, stool, urine, lymphatic fluid, saliva, or some other fluid obtained from the body of the subject 102. In some cases, a blood sample is obtained intravenously from the subject 102. The liquid biopsy sample, according to various examples, is a plasma sample obtained from the blood of the subject 102. In various examples, the liquid biopsy sample includes cell-free DNA (cfDNA) and / or cell-free RNA (cfRNA). In various examples, the liquid biopsy sample includes circulating tumor DNA (ctDNA) and / or circulating tumor RNA (ctRNA). The liquid biopsy sample, for instance, can be obtained in a minimally invasive procedure, which could be performed by a medical technician rather than a surgeon. In some examples, the data analyzer 118 and / or the predictive model 126 may determine, basedFMI Docket No.: 0255-WO / 0206-CD L&H Docket No.: F171-6038PCT on the sequence read data 116, that there is sufficient evidence to infer that the lesion 104 would be effectively treated by a particular therapy, or would not be effectively treated by the particular therapy, without further analysis. The sequence read data 116, in some cases, is indicative of fragments in the nucleic acid molecules 112 (e.g., cfDNA, ctRNA, etc.). For instance, the data analyzer 118 may identify one or more patterns in the sequence read data 116 that are associated with a high likelihood of successful treatment by a particular therapy. In some examples, the nucleic acid-based analysis may indicate that the health-related condition would not be effectively treated by a therapy that could be identified using the protein-based analysis. For instance, the data analyzer 118 may identify a lack of patterns in the sequence read data 116 associated with a high likelihood of successful treatment by a particular type of therapy, such as immunotherapy. In some cases, the predictive model 126 may identify one or more patterns that indicate that the lesion 104 will not respond well to a particular type of therapy. In various examples, the predictive model 126 may output an indication of one or more followup tests to identify other types of therapy that may effectively treat the lesion 104 (e.g., chemotherapy). Accordingly, it may be possible to identify whether the lesion 104 would be effectively treated by a particular therapy by performing the nucleic acid-based analysis of the nucleic acid molecules 112, thereby avoiding incurring the risks and costs associated with a protein-based analysis of the proteins 110.
[0119] FIG. 1 illustrates various elements that can be embodied in one or more computing devices. For example, at least a portion of the functions of the sequencer 114, the protein detector 120, the data analyzer 118, the predictive model 126, the report generator 130, or the clinical device 134 are performed by one or more processors in at least one computing device. Examples of computing devices include server computers, desktop computers, laptop computers, tablet computers, mobile phones, wearable devices, Internet of Things (loT) devices, and the like. In various cases, instructions for performing at least a portion of the functions of these elements are stored in memory and / or in a non-transitory computer readable medium. The instructions, for instance, are executed by the processor(s).
[0120] FIG. 1 also illustrates various types of data. For example, the sequence read data 116, the protein data 122, the input features 124, the therapy indicator(s) 128, the report 132, or any combination thereof, includes data. The various types of data illustrated in FIG. 1 may be stored, such as in memory or in non-transitory computer readable media. In various implementations, at least a portion of the data is transmitted or otherwise output by one or more computing devices. For example, a computing device may transmit one or more communication signals to another computing device, wherein the communication signal(s) encode at least a portion of the data. Examples of communication signals include electromagnetic signals, optical signals, ultrasonic signals, optical signals, and electrical signals. For example, communication signals can be transmitted wirelessly and / or in a wired fashion. The communication signals, for instance, are transmitted over one or more wireless channels and / or one or more wired channels (e.g., optical cabling, electrical cabling, etc.). In various cases, the communication signal(s) are transmitted over one or more communication networks. A communication network, for instance, may be defined according to one or more physical channels, such as one or more frequency spectra. In some cases, a communication network is defined according to one or more communication protocols and / or standards. Examples of communication networks include fiber optic networks, Institute of Electrical and Electronics Engineers (IEEE) networks (e.g., WI-FI™ networks, WiMAX networks, BLUETOOTH™ networks, etc.), cellular networksFMI Docket No.: 0255-WO / 0206-CD L&H Docket No.: F171-6038PCT (e.g., a 3rdGeneration Partnership Project (3GPP) radio network, such as a Long Term Evolution (LTE) network, a New Radio (NR) network; or a cellular core network such as a 3rdGeneration (3G) core, a 4thGeneration (4G) core, a 5thGeneration (5G) core, etc.), ultrasonic networks, and the like. In some cases, the data is broadcasted from one device to multiple other devices. In some cases, the data is unicasted from one device to another device. For instance, various forms of data described herein may be transmitted via a peer-to-peer (P2P) connection.
[0121] A particular example will now be described with reference to FIG. 1. In this example, the subject 102 presents to a clinical environment for an assessment (e.g., a follow-up visit) of a lung cancer of the subject. The care provider(s) 106 may initiate and / or identify results of medical imaging (e.g., x-ray, CT imaging, PET imaging) on the subject 1-2. In some examples, the care provider(s) 106 may determine a location of the lesion 104 on a lung of the subject 102. The care provider(s) 106 may obtain the sample 108, for instance, by performing a biopsy procedure on the lesion 104.
[0122] In various cases, the sequencer 114 may generate sequence read data 116 based on the nucleic acid molecules 112 in the sample 108 of the subject 102. The sequence read data 116 may represent the presence and / or the level of one or more genes associated with the protein(s)-of-interest (e.g., a protein associated with lung cancer). For instance, the subject 102 may be diagnosed with NSCLC, and the one or more genes may include ALK, CD274, EGFR, ERBB2, MET, ROS1, and TACSTD2 In various examples, the data analyzer 118 may identify the protein-of-interest by analyzing the sequence read data 116.
[0123] In various cases, the protein detector 120 may generate protein data 122 based on the proteins 110 in the sample 108 of the subject 102. For example, the protein data 122 may represent the presence and / or the level of the protein(s)-of-interest. In some examples, the data analyzer 118 may determine input feature(s) 124 based on the protein data 122 and / or the sequence read data 116. In various instances, the input feature(s) 124 are indicative of other features of the subject 102 and / or the sample 108 that are indicative of lung cancer (e.g., whole-genome sequencing data, clinicopathological data, etc.). The predictive model 126 may generate the therapy indicator(s) 128 based on the input feature(s) 124. The therapy indicator(s) 128 may indicate one or more therapies predicted to effectively treat the lesion 104. In particular implementations, the therapy indicator(s) 128 indicate a particular immunotherapy predicted to effectively treat the lesion 104 based on at least the expression of the protein-of-interest in the sample 108. Accordingly, the report generator 130 may output a report 132 indicative of the therapy indicator(s) 128 to a clinical device 134. Based on receiving the report 132 using the clinical device 134, the care provider(s) 106 may administer the indicated therapy to the subject 102.
[0124] FIG. 2 illustrates an example environment 200 for training and utilizing a predictive model 202 to identify one or more proteins-of-interest associated with a therapy predicted to effectively treat a health-related condition. The predictive model 202, for instance, is the predictive model 126 described above with reference to FIG. 1. In various implementations, the predictive model 202 includes a classifier 204, which may include one or more ML models. A trainer 206, for instance, is configured to optimize various parameters 208 of the classifier 204 based on training data 210.
[0125] The training data 210 includes example features 212 and example categories 214. The example features 212, in various cases, are obtained based on nucleic acid molecules (e.g., DNA and / or RNA) and proteins of individuals within aFMI Docket No.: 0255-WO / 0206-CD L&H Docket No.: F171-6038PCT population 216. The example categories 214 may include categorizations of pathologies experienced by the individuals within the population 216. For example, the example categories 214 may be generated based on clinical evaluations of the individuals within the population 216, such as by one or more care providers.
[0126] The classifier 204 include one or more model types. For instance, the classifier 204 include an artificial neural network. An artificial neural network includes various layers that respectively process input data. For example, an artificial neural network includes an input layer, one or more hidden layers, and an output layer. The input layer performs a preprocessing operation on the input data. The hidden layer(s) may perform various processing operations on the output from the input layer. The output layer, in various cases, processes the output from the hidden layer(s). Each layer, in some cases, includes one or more nodes, which are defined by individual operations. In various cases, the hidden layer(s) include nodes that are connected to each other in parallel and / or series. Examples of artificial neural networks include feedforward neural networks, multi-layer perceptrons (MLPs), convolutional neural networks (CNNs), and backpropagation models. In various implementations, the operations performed by the layers and / or nodes within an artificial neural network included in the classifier 204 is defined according to the parameters 208. For example, the parameters 208 may include weights, thresholds, filters, kernels, or other data objects that are utilized to perform operations of the classifier 204.
[0127] In some implementations, the classifier 204 include a nearest-neighbor model. One example of a nearest-neighbor model includes a k-nearest neighbor model. For example, a nearest-neighbor model defines various "neighbors,” which are points within a feature space, with associated class labels. When a new data point is mapped to the feature space, the new data point is classified based on the proximity (e.g., Euclidian distance, Manhattan distance, Minkowski distance, etc.) of its “neighbors" to the new data point as well as their associated classes. In some cases, the new data point is classified as belonging to a particular class if greater than a threshold number of neighbors within a threshold distance of the new data point are members of the class. For instance, the parameters 208 may include k (e.g., the number of neighbors compared to the new data point), the threshold distance, and so on.
[0128] In various cases, the classifier 204 include a regression analysis model. The regression analysis model, for example, is defined by a regression function that defines relationships between one or more independent variables and one or more dependent variables. The regression function may further define one or more unknown parameters that define a relationship between the independent and dependent variables. In various implementations, the unknown parameters and / or the type of regression function (e g., linear, quadratic, etc ), is defined according to the parameters 208.
[0129] In some cases, the classifier 204 include a clustering model. In various cases, a clustering model maps various data points (e.g., training data) to a feature space. Based on the proximity of groups of those data points in the features pace, one or more “clusters” are defined. An additional data point may be classified according to one or more of the clusters based on its proximity to the clusters (e.g., a center of the clusters, a boundary of the cluster, etc.). Examples of clustering models include k-means clustering, mean-shift clustering, expectation-maximization (EM) clustering, and agglomerative hierarchical clustering. The parameter(s) 208, for example, include a threshold proximity within which a new data point is classified within a cluster, a density of points used to define a cluster, and the like.FMI Docket No.: 0255-WO / 0206-CD L&H Docket No.: F171-6038PCT
[0130] In various examples, the classifier 204 include a principal component analysis model. In various implementations, a principal component analysis defines a collection principal components of unit vectors within a coordinate space based on a data set (e.g. , training data). The model, for example, is an orthogonal linear transformation of the data set. Various weights of the model, for example, are included in the parameter(s) 208.
[0131] The classifier 204, in some implementations, includes a gradient boosting model. For example, the gradient boosting model is defined as a collection of prediction models (e.g., decision trees) that iteratively classify observed data. In various cases, the type of prediction model, weights in the prediction models, and the like, are defined by the parameter(s) 208.
[0132] The classifier 204, for example, includes a random forest. The random forest, for instance, includes multiple decision trees that classify data in an ensemble fashion. In various implementations, the decision trees are defined by the parameter(s) 208.
[0133] In various implementations of the present disclosure, the trainer 206 is configured to optimize the parameters 208 based on the training data 210. For example, the trainer 206 may input first example features (corresponding to a first individual among the population 216) among the example features 212 into the predictive model 202, and may receive a predicted category. The trainer 206 may compute a loss (e.g., determine a discrepancy) between a first example category (corresponding to the first individual) among the example categories 214 and the predicted category. Further, the trainer 206 may alter the parameters 208 in order to minimize the loss. In various cases, the trainer 206 optimizes the parameters 208 iteratively based on the entire set of the training data 210.
[0134] In various implementations, the optimization of the parameters 208 enables the predictive model W02 to identify predictive attributes of the example features 212 that are correlated to or otherwise associated with the example categories 214. For instance, the predictive model 202 may determine that a particular end motif sequence represented in the example features 212 is highly correlated with adenosarcoma. The predictive model 202 may therefore classify cancers based on features outside of the example features 212 by recognizing or otherwise identifying the predictive attributes.
[0135] Once the parameters 208 are optimized, the predictive model 202 may be ready to classify a new set of data. For example, the predictive model 202 may receive input data including features 218 of a subject. The features 218, for instance, may include one or more of the predictive attributes. The predictive model 202 may perform various operations on the input data based on the trained classifier 204 and the optimized parameters 208. In various cases, the predictive model 202 outputs output data including one or more category indicators 220 based on the features 218. The category indicator(s) 220, for instance, include one or more predicted therapies that effectively treat a cancer experienced by the subject.
[0136] Although FIG. 2 is primarily described as referring to supervised learning, implementations are not so limited. In various cases, the training data 210 omits the example categories 214 and the trainer 206 is configured to optimize the parameters 208 using the example features 212 and an unsupervised learning technique.
[0137] FIG. 3 illustrates an example of training data 300 utilized to train one or more ML models. For example, the training data 300 may be the training data 210 described above with reference to FIG. 2.FMI Docket No.: 0255-WO / 0206-CD L&H Docket No.: F171-6038PCT
[0138] The training data 300, in various cases, may represent m samples, wherein m is a positive integer. In some cases, the m samples are respectively obtained from m individuals within a population, although implementations are not so limited. For example, in some cases, multiple samples may be obtained from the same individual at different times.
[0139] The training data 300 includes first to mth example features 302-1 to 302-m. For example, the first to mth example features 302-1 to 302-m include features derived from proteins and / or nucleic acid molecules in the respective m samples.
[0140] The training data 300 may further include first to mth example categories 404-1 to 404-m. The first to mth example categories 304-1 to 304-m, for instance, include categories or classifications of cancers represented by the m samples. In some examples, the first to mth example categories 304-1 to 304-m include one or more therapy categories (e.g., a susceptibility of the tumor cells to a treatment, a resistance of the tumor cells to a treatment) represented by the m samples.
[0141] FIG. 4 illustrates an example report 400 summarizing predicted categories of a cancer of a subject. In various cases, the report 400 is the report 132 described above with reference to FIG. 1. The report 400, for instance, may be displayed to a patient and / or care provider. In some cases, the report 400 is generated based on features of a sample obtained from the subject.
[0142] In various cases, the report 400 includes one or more therapy indicators 402. For instance, the therapy indicator(s) 402 convey whether the cancer is predicted to be resistant to one or more predetermined therapies and / or whether the cancer is predicted to be responsive to one or more predetermined therapies.
[0143] In some examples, the report 400 includes one or more prognostic indicators 404. The prognostic indicator(s) 404, for instance, indicate a prognosis of the subject in view of the categorized cancer. For example, the prognostic indicator(s) 404 may indicate a survivability, a recoverability, a quality of life indicator, or other information indicative of the prognosis of the subject.
[0144] The report 400 includes a tissue origin 406 of the cancer. The tissue origin 406, for instance, indicates a histological tissue type 408, a primary site 410, cell subtype 412, or any combination, of the cancer.
[0145] The report 400 may include atrial qualification 414 of the subject. The trial qualification 414, for instance, indicates whether the subject is predicted to qualify for a predetermined clinical trial.
[0146] The report 400, in various implementations, includes a metastasis profile 416 of the subject. The metastasis profile 416, for instance, indicates a likelihood that the cancer will metastasize (e.g., at a particular point in time), one or more tissues in which the cancer is predicted to metastasize, or the like.
[0147] The report 400, in some examples, includes an indication of nucleic acid-based test results 417 of the subject. For instance, the nucleic acid-based test results 417 may indicate one or more genes indicated by the nucleic acid-based test (e.g., a gene associated with an expression level above a threshold expression level) and / or one or more proteins-of-interest associated with the indicated gene(s). The nucleic acid-based test results 417 may include a recommendation to perform protein-based testing (e.g., IHC) on the protein(s)-of-interest.
[0148] In various cases, the report 400 includes recommended follow-up tests 418. For example, the report 400 may include a recommendation to perform whole genome sequencing on the subject, particularly in cases if the cancer cannot be categorized above a threshold certainty.FMI Docket No.: 0255-WO / 0206-CD L&H Docket No.: F171-6038PCT
[0149] The report 400 may include a genomic profile 420 of the subject. In various cases, the genomic profile 420 includes or is generated based on the results of non-fragmentomic analyses of the subject.
[0150] FIG. 5 illustrates an example environment 500 for sequencing various nucleic acid molecules 502. In various implementations, the nucleic acid molecules 502 include DNA and / or RNA. The nucleic acid molecules 502, in various cases, are extracted from a sample, such as a biological sample obtained from a subject. In some implementations, the nucleic acid molecules 502 include DNA that is complementary to RNA present in the sample.
[0151] The nucleic acid molecules 502, in various cases, are ligated with adapters 504. For examples, the adapters 504 are hybridized to the nucleic acid molecules 502. The adapters 504, for example, include additional nucleic acid molecules. In various implementations, the adapters 504 have a shorter length than the nucleic acid molecules 502 being sequenced. For instance, the adapters 504 include amplification primers, flow cell adapter sequences, substrate adapter sequences, or sample index sequences. Although FIG. 5 illustrates adapters 504 being ligated to one end of each of the nucleic acid molecules 502, implementations are not so limited. For example, the adapters 504 may be ligated to both ends of each of the nucleic acid molecules 502.
[0152] In various examples, the nucleic acid molecules 502 ligated with the adapters 504 are amplified in order to generate amplified molecules 506. Various amplification techniques can be performed. For instance, the amplified molecules 506 are generated using PCR, a non-PCR amplification technique, an isothermal amplification technique, or any combination thereof.
[0153] Amplified molecules 506 may be captured by bait molecules 510 and sequenced. In some implementations, the amplified molecules 506 are sequenced via sequencing-by-synthesis. In various cases, fluorescently tagged deoxyribonucleotide triphosphates (dNTP) 512 are utilized to synthesize a strand that is complementary to DNA strands bound to the substrate 508. When a dNTP 512 is added to the strand (e.g. , by an enzyme), the dNTP 512 emits an optical signal 514. In various implementations, the frequency of the optical signal 514 is dependent on the type of dNTP 512 from which the optical signal 514 is emitted. By detecting the optical signals 514 as the strand is being synthesized, the sequence of the original nucleic acid molecules 502 can be derived.
[0154] In some implementations, the amplified molecules 506 are sequenced via nanopore sequencing. For instance, the amplified molecules 506 are directed through a nanopore 516 extending through a substrate 518. In various cases, the amplified molecules 506 are negatively charged, such that they can be directed through the nanopore 516 by imposing an electrical field across the substrate 518. In various cases, the amplified molecules 506 and the nanopore 516 are in the presence of a charged solution. Thus, charged solutes traveling through the nanopore 516 can be monitored by reviewing an electrical signal (e.g., a current) sensed between electrodes 520 on either side of the substrate 518. As an amplified molecule 506 is directed through the nanopore 516, the individual bases within the amplified molecule 506 will block the nanopore 516, which may decrease the amount of charged solutes traveling through the nanopore 516 and consequently, the magnitude of the electrical signal detected by the electrodes 520. Each of the four types of bases within the amplified molecules 506, may block the nanopore 516 to a different extent. Therefore, the sequence of the nucleic acid moleculesFMI Docket No.: 0255-WO / 0206-CD L&H Docket No.: F171-6038PCT 502 can be derived by analyzing the measured electrical signal with respect to time as the amplified molecules 506 are directed through the nanopore 516.
[0155] FIG. 6 illustrates an example process 600 for identifying a therapy predicted to effectively treat a health-related condition of a subject based on identifying one or more proteins-of-interest in a nucleic acid-based analysis. In various implementations, the process 600 is performed by an entity including at least one processor, at least one computing device, a medical device, the sequencer 114, the protein detector 120, the data analyzer 118, the predictive model 126, the report generator 130, the clinical device 134, or any combination thereof.
[0156] In some examples, at 602, the entity identifies sequence read data indicative of nucleic acid molecules in a sample of the subject. For instance, the entity receives a plurality of nucleic acid molecules in the first portion of the sample of the subject. The nucleic acid molecules, for instance, include DNA (e.g., genomic DNA) and / or RNAfrom the sample. In some instances, the entity determines the RNA expression of one or more genes of the subject. The sample may include a tissue sample or liquid sample (e.g., a blood sample, a urine sample, a saliva sample, etc.). In some examples, the tissue sample is obtained from a tumor of the subject. The nucleic acid molecules, for instance, include RNA molecules from the sample. The RNA molecules may be reverse transcribed into cDNA molecules. One or more adapters are ligated onto at least some of the cDNA molecules. The ligated cDNA molecules are amplified and captured. In various cases, all or a subset of the captured cDNA molecules are sequenced to obtain a plurality of sequence reads that represent the sequenced amplified cDNA molecules, thereby generating the sequence read data.
[0157] At 604, the entity determines the protein(s)-of-interest based on the sequence read data. In various cases, the protein(s)-of-interest may be identified based on determining that the RNA expression of one or more genes is above a threshold. In some examples, the entity may analyze the RNA expression of the gene associated with a protein-of-interest. In some examples, the entity may analyze the RNA expression of a panel of genes associated with the protein(s)-of-interest. In some examples, the entity may analyze the genomic information (e.g., the genetic loci) associated with the protein(s)-of-interest. In various cases, the protein(s)-of-interest are associated with one or more therapies indicated to treat the health-related condition of the subject.
[0158] At 606, the entity identifies protein data indicative of the protein (s)-of-interest. In various examples, the protein (s)-of-interest may be tagged with a capture agent (e.g., a ligand configured to specifically bind to a protein-of-interest). In some cases, the capture agent is applied to the sample (e.g., a tissue sample obtained from a lesion of the subject). The tagged sample may be visualized (e.g., imaged) to determine the presence, level, or distribution of the protein (s)-of-interest.
[0159] At 608, the entity identifies a therapy predicted to effectively treat the health-related condition of the subject. In various cases, the entity inputs the sequence read data and / or the protein data into a machine learning (ML)-based classifier to identify the therapy. The ML-based classifier, for instance, is pre-trained based on data obtained from a population of individuals that omits the subject. In some cases, the classifier includes at least one of an artificial neural network (ANN), a logistic regression model, a decision tree, a k-nearest neighbor (KNN) model, a support vector machine (SVM), or a naive Bayes classifier. In some cases, the classifier outputs a likelihood that the therapy is predicted to effectively treat the health-related condition (or that the therapy is predicted to ineffectively treat the health-relatedFMI Docket No.: 0255-WO / 0206-CD L&H Docket No.: F171-6038PCT condition). In some cases, the classifier outputs an indication that the therapy is predicted to effectively treat the health-related condition when the likelihood exceeds a threshold likelihood.
[0160] FIG. 7 illustrates one or more devices 700 configured to perform various operations described herein. The device(s) 700 include one or more processor(s) 702. In some implementations, the processor(s) 702 includes a central processing unit (CPU), a graphics processing unit (GPU), both CPU and GPU, or other processing unit or component known in the art.
[0161] The processor(s) 702 is operably connected to memory 704. In various implementations, the memory 704 is volatile (such as random access memory (RAM)), non-volatile (such as read only memory (ROM), flash memory, etc.) or some combination of the two. The memory 704 stores instructions that, when executed by the processor(s) 702, causes the processor(s) 702 to perform various operations. In various examples, the memory 704 stores methods, threads, processes, applications, objects, modules, any other sort of executable instruction, or a combination thereof. In some cases, the memory 704 stores files, databases, or a combination thereof. In some examples, the memory 704 includes, but is not limited to, RAM, ROM, electrically erasable programmable read-only memory (EEPROM), flash memory, or any other memory technology. In some examples, the memory 704 includes one or more of CD-ROMs, digital versatile discs (DVDs), content-addressable memory (CAM), or other optical storage, magnetic cassettes, magnetic tape, magnetic disk storage or other magnetic storage devices, or any other medium which can be used to store the desired information and which can be accessed by the processor(s) 702. For instance, the memory 704 stores instructions that, when executed by the processor(s) 702, causes the processor(s) 702 to perform operations of the data analyzer 118, the predictive model 126, and the report generator 130.
[0162] The processor(s) 702 is operably connected to one or more input devices 706 and one or more output devices 708. Collectively, the input device(s) 706 and the output device(s) 708 function as an interface between at least one user and the device(s) 700. The input device(s) 706 is configured to receive an input from a user and includes at least one of a keypad, a cursor control, a touch-sensitive display, a voice input device (e.g., a microphone), a haptic feedback device (e.g., a gyroscope), or any combination thereof. The output device(s) 708 includes at least one of a display, a speaker, a haptic output device, a printer, or any combination thereof. In various examples, the processor(s) 702 causes a display among the input device(s) 706 to visually output various data described herein. In some implementations, the input device(s) 706 includes one or more touch sensors, the output device(s) 708 includes a display screen, and the touch sensor(s) are integrated with the display screen.
[0163] In various implementations, the processor(s) 702 is operably connected to one or more transceivers 710 that transmit and / or receive data over one or more communication networks 712. For example, the transceiver(s) 710 includes a network interface card (NIC), a network adapter, a local area network (LAN) adapter, or a physical, virtual, or logical address to connect to the various external devices and / or systems. In various examples, the transceiver(s) 710 includes any sort of wireless transceivers capable of engaging in wireless communication (e.g., radio frequency (RF) communication). For example, the communication network(s) 712 includes one or more wireless networks that include a 3rd Generation Partnership Project (3GPP) network, such as a Long Term Evolution (LTE) radio access network (RAN)FMI Docket No.: 0255-WO / 0206-CD L&H Docket No.: F171-6038PCT (e.g., over one or more LTE bands), a New Radio (NR) RAN (e.g., over one or more NR bands), or a combination thereof. In some cases, the transceiver(s) 710 includes other wireless modems, such as a modem for engaging in WI-FI®, WIGIG®, WIMAX®, BLUETOOTH®, or infrared communication over the communication network(s) 712.
[0164] The device(s) 700 may further include the sequencer 114. In various implementations, the sequencer 114 includes one or more fluidic circuits 714 configured to receive a sample 716 derived from a subject 718. The sequencer 114, in various cases, may be configured to generate data indicative of one or more sequences of nucleic acid molecules (e.g., DNA and / or RNA) present in the sample 716. In various cases, the sequencer 114 introduces one or more reagents 719 to the fluidic circuit(s) 714 in order to prepare for and perform sequencing of the nucleic acid molecules. Further, the sequencer 114 may include one or more sensors 720 configured to measure or otherwise detect detection signals from the fluidic circuit(s) 714, which may be indicative of the sequences of the nucleic acid molecules. According to various implementations, the sensor(s) 720 may further include one or more ADCs. The sequencer 114, in various cases, outputs sequence read data to the processor(s) 702 for additional processing.Example Clauses1. A method including: providing a plurality of RNA molecules obtained from a first tissue sample from a tumor of a subject; generating a plurality of nucleic acid molecules by reverse transcribing the RNA molecules; ligating one or more adapters onto one or more nucleic acid molecules from the plurality of nucleic acid molecules; amplifying the one or more ligated nucleic acid molecules from the plurality of nucleic acid molecules; capturing amplified nucleic acid molecules from the amplified nucleic acid molecules; sequencing, by a sequencer, all or a subset of the captured amplified nucleic acid molecules to obtain a plurality of sequence reads that represent the sequenced amplified nucleic acid molecules thereby generating sequence read data; receiving, at one or more processors, the sequence read data for the plurality of sequence reads; determining, by the one or more processors and based on the sequence read data, RNA expression of multiple genes in the first tissue sample; identifying an expressed gene of the multiple genes by comparing the RNA expression of the multiple genes in the first tissue sample to predetermined thresholds; outputting, by the one or more processors, a recommendation to perform an immunohistochemistry (IHC) study of the expressed gene on a second tissue sample of the tumor of the subject; receiving, at the one or more processors, expression data indicative of protein expression of the expressed gene in the second tissue sample; predicting that a therapy will be effective to treat the tumor of the subject based at least in part on the expression data; and based on predicting that the therapy will be effective to treat the tumor of the subject, administering the therapy to the subject.2. The method of clause 1 , further including: receiving a tissue biopsy sample from the tumor of the subject; and collecting, from the tissue biopsy sample, the first tissue sample and the second tissue sample.3. The method of clause 1 or 2, further including: applying, to the tissue sample, a capture agent configured to bind to a protein associated with the gene in the tissue sample; applying, to the tissue sample, a substrate configured to bind to the capture agent; generating, using the substrate, detection signals; and detecting, by at least one sensor, the detection signals, thereby generating the expression data indicative of the protein expression of the gene in the tissue sample.FMI Docket No.: 0255-WO / 0206-CD L&H Docket No.: F171-6038PCT 4. The method of any of clauses 1-3, wherein predicting that the therapy will be effective to treat the tumor of the subject is based on the expression data and the sequence read data.5. The method of clause 4, wherein predicting that the therapy will be effective to treat the tumor of the subject includes: generating, by the one or more processors, input features based on the sequence read data and the expression data, and determining, using a classifier, a likelihood that the therapy will be effective to treat the tumor of the subject.6. The method of any of clauses 1-5, further including: identifying clinicopathological features and / or genomic features of the subject, wherein predicting the therapy will be effective is further based on the clinicopathological features and / or the genomic features.7. The method of any of clauses 1-6, wherein the predetermined thresholds correspond to a type or a subtype of cancer of the subject.8. The method of clause 7, wherein the cancer of the subject includes thyroid cancer, lung cancer, non-small cell lung cancer, pancreatic cancer, prostate cancer, colorectal cancer, gastric cancer, breast cancer, or endometrial cancer.9. The method of any of clauses 1-8, wherein the therapy includes an antibody-drug conjugate or an immune checkpoint inhibitor.10. The method of any of clauses 1-9, wherein the therapy includes an immunotherapy, a targeted therapy, or a personalized therapy, a targeted therapy, or a personalized therapy.11. A method including: identifying sequence read data representing RNA in a first sample of a subject; determining RNA expression metrics of a plurality of genes; identifying, based on the RNA expression metrics of the plurality of genes, a candidate gene of the plurality of genes; receiving, based on identifying the candidate gene, expression data indicative of protein expression of the candidate gene in a second sample of a subject; and predicting, based on the expression data, whether a therapy would be effective at treating a condition of the subject.12. The method of clause 11, wherein the sequence read data corresponds to multiple genomic loci.13. The method of clause 11 or 12, wherein the sequence read data indicates a predetermined panel of genes of the first sample, the predetermined panel including the candidate gene.14. The method of clause 13, wherein the predetermined panel includes one or more of AXL, CCNE1, CD3D, CD3E, CD3G, CD8A, CD8B, CD19, CD22, CD33, CD68, CD79B, CD276, CEACAM5, CEACAM8, CLDN18, DLL3, ERBB2, ERBB3, ESR1, FGFR2b, FOLR1, FOXP3, GZMB, HAVCR2, IL2RA, IL3RA, MET, MGMT, MKI67, MS4A1, MTAP, NCAM1, PDCD1, PTEN, ROR1, RORyT, SLC39A6, TACSTD2, TGFB1, TIGIT, TNFRSF8, or TREM2.15. The method of clause 13, wherein the predetermined panel includes one or more of A2M, ABCA6, ABCB1, ABCC2, ABCC9, ABI1, ABL1, ABL2, ACACA, ACLY, ACRBP, ACSL3, ACSL6, ACTA2, ACTG1, ACTG2, ACTN1, ACTR3B, ACVR1, ACVR1C, ACVRL1, ADAM12, ADAM19, ADAM2, ADCY7, ADGRB1, ADGRB3, ADGRF5, ADGRL4, ADRB2, MLLT10, AFF1, AFF3, AFF4, AFP, AGR2, AGR3, AHR, AIFM3, AKT1, AKT2, AKT3, ALDH2, ALK, ALOX12, AMZ1, ANGPT1, ANGPT2, ANLN, ANPEP, ANXA1, ANXA2, APC, APCDD1, APEX2, APH1A, APLN, APOBEC3A, APOBEC3B, APOBR, APOL6, APP, APPBP2, AR, AREG, ARF1, ARG2, ARHGAP15, ARHGDIA, ARID1A, ARID1B, ARID3A, ARNT, ARNT2, ASAP2, ASB13, ASCL2, ASGR2, ASTE1, ASXL1, ATAD2, ATIC, ATM, ATP2C1, ATP8A1,FMI Docket No.: 0255-WO / 0206-CD L&H Docket No.: F171-6038PCT ATP8B2, ATR, AURKA, AURKB, AVPR1A, AXIN2, AXL, B2M, B3GNT5, BAALC, BAG1, BAG2, BAGE4, BAK1, BAMBI, BAP1, BASP1, BATF, BATF3, BAX, BAZ2B, BCAM, BCAR1, BCAR3, BCAS1, BCL10, BCL11A, BCL11B, BCL2, BCL2A1, BCL2L1, BCL2L11, BCL3, BCL6, BCL7A, NBEAP1, BCL9, BCOR, BCR, BIN2, BIRC3, BIRC5, BLK, BLM, BLNK, BLVRA, BMF, BMP2, BMP4, BMPR1A, BMPR1B, BNC2, BRAF, BRCA1, BRCA2, BRD3, BRD4, BRDT, BRINP3, BRIP1, BRPF1, BTG1, BTG3, BTK, BTLA, BUB1, BUB1B, C10orf35, EMSY, C15orf48, C1RL, C3, C5, C5AR2, CA4, CAGE1, CALB2, CALML3, CALR, CAMTA1, CANX, CASP1, CASP3, CASP8, CASP9, CBFA2T3, CBFB, CBL, CBLC, CCDC140, CCDC50, CCL11, CCL13, CCL14, CCL17, CCL18, CCL19, CCL2, CCL20, CCL21, CCL3, CCL4, CCL5, CCL8, CCNA2, CCNB1, CCNB2, CCND1, CCND2, CCND3, CCNE1, CCNE2, CCNG2, CCR4, CCR5, CCR7, CCR8, CCRL2, CCSER2, CD14, CD163, CD19, CD1A, CD1B, CD1D, CD1E, CD2, CD209, CD22, CD226, CD244, CD247, CD248, CD27, CD276, CD28, CD33, CD34, CD36, CD38, CD3D, CD3E, CD3G, CD4, CD40, CD40LG, CD44, CD46, CD47, CD5, CD6, CD63, CD68, CD7, CD70, CD74, CD79A, CD79B, CD80, CD81, CD84, CD86, CD8A, CD8B, CD9, CD93, CD96, CDC20, CDC25C, CDC45, CDC6, CDCA3, CDCA5, CDCA7, CDCA7L, CDCA8, CDH1, CDH3, CDH5, CDHR1, CDK2, CDK4, CDK6, CDK8, CDKN1A, CDKN1B, CDKN1C, CDKN2A, CDKN2AIP, CDKN2B, CDKN2B-AS1, CDKN2D, CDKN3, CDT1, CDX2, CEACAM1, CEACAM3, CEACAM5, CEACAM8, CEBPA, CEBPB, CELSR2, CENPA, CENPF, CENPM, CNTRL, CEP55, CES1, CES2, CFD, CHAF1B, CHEK1, CHEK2, CHN1, CHUK, CIC, CIITA, CITED4, CLCA2, CLDN18, CLDN3, CLDN4, CLDN5, CLDN6, CLDN7, CLEC10A, CLEC14A, CLEC4C, CLEC5A, CLEC9A, CLIC2, CLIC4, CLTC, CMKLR1, CMPK2, CNN1, CNTNAP2, COL15A1, COL18A1, COL1A1, COL1A2, COL3A1, COL4A1, COL4A2, COL6A3, COL7A1, COPB2, CPA3, CRAT, CREB1, CREB3L1, CREB3L2, CREBBP, CRKL, CRLF2, CRNDE, CRYAB, CSF1, CSF1R, CSF2, CSF3R, CSMD1, CSNK1E, CSNK1G2, CST7, CT45A1, CT45A2, CT45A3, CT62, CTAG1A, CTAG1B, CTAG2, CTAGE1, CTGF, CTLA4, CTNNB1, CTNNBIP1, CTPS1, CTPS2, CTSV, CTSW, CUX1, CX3CL1, CXCL1, CXCL10, CXCL11, CXCL12, CXCL13, CXCL2, CXCL3, CXCL6, CXCL8, CXCL9, CXCR1, CXCR2, CXCR4, CXCR5, CXCR6, CXXC5, CYB5R2, CYBB, CYLD, CYP4F3, DCAF12, DCLK1, DCN, DDB2, DDIT3, DDIT4, DDR1, DDR2, DDX10, DDX21, DDX4, DDX58, DDX6, DEK, DENND3, DEPTOR, DHH, DHX58, DIDO1, DIRC2, DKK1, DKK2, DKK4, DLC1, DLL3, DLL4, DMBT1, DMD, DNMT1, DNMT3A, DOCK5, DOTH, DRAM1, DSC2, DSCR8, DTL, DTX1, DTX2, DTX3L, DUSP1, DUSP18, DUSP22, DUSP6, DVL1, TCF3, E2F1, E2F4, E2F5, EBF1, ECSCR, ECT2, EDNRB, EGF, EGFR, EGLN3, EGR1, EGR2, EIF4A2, ELF4, ELF5, ELK4, ELL, ELN, EMCN, EME1, EML4, EML6, MLLT1, ENTPD1, EOMES, EP300, EP400, EPCAM, EPHA4, EPHA7, EPOR, EPS15, ERAP1, ERAP2, ERBB2, ERBB3, ERCC1, ERCC2, ERCC3, ERCC4, ERCC5, EREG, ERG, ERN2, ESM1 , ESR1, RUNX1T1, ETS1, ETV1, ETV4, ETV5, ETV6, EWSR1, EXO1, EZH2, F11R, FAM101B, AMER1, FAM171B, FAM26F, FAM46A, FAM64A, FANCA, FANCB, FANCC, FANCD2, FAP, FAS, FASN, FAT2, FBXW11, FBXW7, FCAR, FCGR2B, FCGR3B, FCRL2, FCRL5, FEV, FGF9, FGFBP2, FGFR1, CEP43, FGFR2, FGFR3, FGFR4, FGR, FKBP4, FLU, FLNA, FLT1, FLT3, FLT3LG, FLT4, FMN1, FMN2, FMOD, FN1, FNBP1, FNIP2, FOLH1, FOLR1, FCS, FOSB, FOXA1, FOXC1, FOXM1, FOXO1, FOXO3, FOXO4, FOXO6, FOXP1, FOXP3, FPR1, FPR3, FSTL3, FUCA1, FUS, FUT4, FUT8, FZD1, FZD10, FZD2, FZD5, FZD6, FZD7, GABBR2, GADD45A, GADD45B, GAGE1, GAGE2E, GAGE6, GAGE8, GALNT10, GALNT12, GAS1, GAS7, GBP5, GIMAP5, GIMAP7, GINS2, GJA4, GLI1, GLIS2, GMFG, GMNN, GMPS, GNA12, GNG11, GNLY,FMI Docket No.: 0255-WO / 0206-CD L&H Docket No.: F171-6038PCT GOLM1, GPA33, GPC4, GPC6, GPI, GPR143, GPR146, GPR160, ARHGAP26, GRB7, GREB1, GRM4, GSK3B, GSTA1, GSTM1, GUSB, GZMA, GZMB, GZMH, GZMK, H2AFX, HABP2, HAMP, HAP1, HAVCR2, HBEGF, HCLS1, HCST, HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9, HDC, HELZ2, HERPUD1, HES1, HES2, HES4, HES5, HES6, HEY1, HEY2, HEYL, HGF, HHIP, HIF1A, HIP1, HIST1H1A, H1-4, H2AC11, HIST1H2AI, HIST1H2BL, H3C2, HIST2H2BF, HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DQA1, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-E, HLF, HMGA1, HMGA2, HMGCS2, HMMR, HOPX, HORMAD1, HOXA11, HOXB2, HPCAL1, HRAS, HRASLS, HSD11B1, HSP90AA1, HSP90AB1, HSPA4L, HSPB1, ICAM1, ICAM2, ICOS, ID1, ID2, IDO1, IFI16, IFI27, IFI35, IFI6, IFIT1, IFIT2, IFIT3, IFITM2, IFITM3, IFNG, IFNL2, IGF1, IGF1R, IGFBP1, IGFBP3, IGFBP4, IGLL5, IHH, IKBKE, IKZF1, IKZF2, IKZF3, IL10, IL11, IL12A, IL13, IL13RA2, IL15, IL16, IL17RA, IL1A, IL1B, IL1R1, IL1RN, IL21R, IL23A, IL2RA, IL3, IL33, IL3RA, IL4R, IL6, IL6R, IL6ST, IL7, IL7R, IMPDH1, INPP1, INSR, INSRR, IPO8, IQGAP3, IRF1, IRF4, IRF7, IRF8, IRGM, IRS2, IRX4, ISG20, ISY1, ITGAM, ITGAV, ITGAX, ITGB1, ITGB2, ITGB4, ITK, ITM2A, ITPKB, JAK1, JAK2, JAK3, JAML, JAZF1, JUN, KCNE3, KCNJ15, KCNK5, KCNMA1, KDM1A, KDM3B, KDM4C, KDM5C, KDM5D, KDR, KDSR, KIAA0040, KIAA0125, KIAA0319L, KIAA1462, KIAA1804, KIF13B, KIF23, KIF2B, KIF2C, KIF5B, KIFC1, KIR2DL1, KIR2DL3, KIR3DL1, KIR3DL2, KIR3DS1, KIT, KLF2, KLF4, KLK3, KLRB1, KLRC3, KLRC4, KLRD1, KLRK1, KMT5A, KRAS, KRT14, KRT17, KRT31, KRT5, KRT6A, KRTCAP3, KYNU, LAG3, LAIR1, LAMB1, LASP1, LATS1, LATS2, LCK, LCN2, LCP1, LDHB, LEF1, LGALS2, LGALS3, LILRB5, LIMD1, LIMK2, LINC-ROR, LINC00598, LIPH, LIPI, LMNA, LMO1, LMO2, LMO3, LMO4, LGC100506207, LGC100507346, LGC100507424, LPP, LRMP, LRP1, LRP8, LRRC15, LTF, LTK, LUZP4, LY6E, LY6G6D, LYL1, LZTR1, MACC1, MAF, MAFB, MAGEA1, MAGEA10, MAGEA11, MAGEA12, MAGEA2B, MAGEA3, MAGEA4, MAGEA5, MAGEA6, MAGEA8, MAGEA9B, MAGEB1, MAGEB10, MAGEB16, MAGEB17, MAGEB18, MAGEB2, MAGEB3, MAGEB4, MAGEB5, MAGEB6, MAGEC1, MAGEC2, MAGEC3, MALAT1, MALT1, MAML2, MAML3, MAP2, MAP2K1, MAP2K3, MAP3K7, MAP3K8, MAP4K4, MAPK1, MAPK3, MAPKAPK2, MAPT, MARK1, MASP2, MAST1, MAST2, MASTL, MB21D1 , MBTD1, MCAM, MCL1, MCM10, MCM2, MCM4, MCM6, MDC1, MDM2, MDS2, MECOM, MEF2C, MEF2D, MEG3, MEGF9, MELK, MEN1, MEST, MET, METRNL, MFAP4, MFAP5, MGA, MGMT, MGST2, MIA, MIAT, MICB, MIR100, MITF, MKI67, MRTFA, MRTFB, MLF1, MLH1, KMT2A, KMT2D, KMT2C, MLPH, MME, MMP11, MN1, MNX1, MOCOS, MPZL3, MRAS, MRE11, MRVI1, MS4A1, MS4A2, MS4A4A, MSH2, MSH6, MSI2, MSMB, MSN, MST1R, MTAP, MTCP1, MTHFD1L, MTOR, MUC1, MUC16, MUTYH, MVP, MX1, MX2, MYB, MYBL2, MYC, MYCL, MYCN, MYCT1, MYD88, MYH11, MYH9, KAT6A, NAB2, NAT1, NAV3, NBEA, NBN, NCAM1, NCOA2, NCOR1, NCR1, NDC80, NDE1, NDRG1, NEAT1, NECTIN1, NECTIN2, NECTIN3, NEK1, NEK2, NEK6, NELL2, NF1, NF2, NFATC2, NFE2L2, NFIC, NFKB2, NID2, NIN, NKD1, NKG7, NKX3-1, NLK, NONO, NOS1, NOS1AP, NOTCH1, NOTCH2, NOTCH3, NOTCH4, NPAS2, NPM1, NR4A3, NRAP, NRARP, NRAS, NRG1, NRG2, NRP1, NRP2, NRTN, NSD1, NT5C3A, NT5E, NTRK1, NTRK2, NTRK3, NUF2, NUMA1, NUMBL, NUP214, NUP98, NUTM1, NUTM2A, NXF2B, NXPH3, OAS3, OASL, ODC1, OGN, OLFM1, OLFM4, OLIG2, ORAI2, ORC6, P2RY8, PADI2, PAFAH1B2, PAGE5, PAK2, PAK4, PALB2, PAMR1, PARP1, PARP12, PARP14, PAX3, PAX5, PAX7, PAX8, PBK, PBX1, PBX3, PCDH17, PCSK1, PDCD1, PDGFA, PDGFB, PDGFD, PDGFRA, PDGFRB, PDIA3, CD274,FMI Docket No.: 0255-WO / 0206-CD L&H Docket No.: F171-6038PCT PDCD1LG2, PDZK1IP1, PECAM1, PFN2, PGR, PHF1, PHF11, PHGDH, PHLPP1, PICALM, PIK3CA, PIK3CD, PIK3CG, PIK3R1, PIK3R2, PIM2, PIM3, PKN1, PLA2G7, PLAC8, PLAG1, PLAGL2, PLCB4, PLEK2, PLEKHA4, PLEKHB1, PLK2, PLPP3, PLVAP, PMEPA1, PML, PMS1, PMS2, PNOC, PNPLA7, PODXL, POLD1, POLE, POU2F2, POU5F1, PPARG, PPM1J, PPP1R13L, PRDM15, PRDM16, PRF1, PRKACA, PRKACB, PRKACG, PRKCA, PRKCB, PRMT1, PRMT5, PRND, PROM1, PRPF6, PRPF8, PSAT1, PSCA, PSD3, PSENEN, PSIP1 , PSMB10, PSMB8, PSMB9, PSME1, PTCH1, PTCH2, PTCRA, PTEN, PTGDS, PTGER2, PTGER4, PTGS2, PTPN1, PTPN11, PTPN22, PTPRB, PTPRC, PTPRK, PTPRO, PTPRZ1, PTRF, PTTG1, PUM1 , PVR, PVRIG, PXDC1, R3HDM1, RAB23, RAB27A, RAB29, RAC1, RAD50, RAD51, RAD51AP1, RAD51C, RAD51B, RAD51D, RAD52, RAD54L, RAF1, RAPGEFL1, RARA, RASGRF1, RASIP1, RASSF6, RB1, RBL1, RBM24, RBP7, RBX1, RECQL4, REG4, RELA, RERG, RET, RGCC, RGS10, RGS16, RGS2, RHOA, RHOH, RHOJ, RIT1, RNF13, ROBO4, ROCK2, ROPN1, ROPN1B, ROR1, ROR2, RORA, RORC, RORyT, ROS1, RP1, RPL23, RPL39L, RPS26, RPS6KA1, RPS6KB1, RPSAP52, RRAGC, RRAS, RRM2, RSAD2, RSPO2, RSPO3, SNX29, RUNX1, RUNX2, RUNX3, S100A12, S100A8, S1PR2, SAA1, SAGE1, SAMD9L, SAP30, SCD, SCD5, SCML4, SCUBE2, SDC1, SDHA, SDHB, SDHC, SDHD, SEC31A, SELL, SELP, SEMA3E, SEMA4B, SEMA4C, SEMA6D, SEMA7A, SEPT7, SEPT12, SEPTIN5, SEPTIN6, SEPTIN9, SEPW1, SERPINA9, SERPINB13, SERPINB2, SERPINB5, SERPINE1, SERPINF1, SESN1, SESN2, SESN3, SET, SF3B1, SFRP1, SGK3, SH2D1A, SH2D1B, SH2D2A, SH3BP5, SH3GL1, SH3PXD2A, SHCBP1, SHISA5, SHISA8, SHOC2, SIGLEC5, SKP1, SLAMF1, SLC16A3, SLC1A2, SLC22A8, SLC39A6, SLC40A1, SLC45A3, SLC7A8, SLC9A3R1, SLCO2A1, SLFN11, SLIT2, SMAD2, SMAD3, SMAD4, SMAD9, SMARCB1, SMURF2, SNAI1, SNRNP70, SNW1, SOCS1, SOS1, SOS2, SOX11, SOX17, SOX18, SOX9, SP2, SPANXA1, SPANXB1, SPANXC, SPARC, SPARCL1, SPIB, SPINK1, SPN, SPP1, SPRY4, SRC, SRD5A1, SREBF1, SRSF3, SS18, SSPO, SSX1, SSX2, SSX2B, SSX3, SSX4, SSX5, ST3GAL2, STAT1, STAT3, STAT4, STAT6, STAU2, STEAP1, STEAP4, STIL, STK11, STON1, SULF2, SULT1A1, SUV39H2, SYCP1, SYCP3, SYK, TACSTD2, TAF15, TAGAP, TAGLN, TAL1, TAL2, TAP1, TAP2, TAPBP, TBC1D10C, TBC1D4, TBC1D9, TBL1XR1, TBX21, TCF12, TCF4, TCF7L1, TCF7L2, TCL1A, TCL6, TDG, TDGF1, TDRD7, TEAD1, TEC, TEK, TENM3, TERC, TERT, TET1, TET2, TET3, TFCP2L1, TFE3, TFEB, TFF1, TFG, TFPT, TFRC, TGFB1, TGFB2, TGFB3, TGFBI, TGFBR1, TGFBR2, THADA, THBD, THBS1, THY1, TIAM1, TIE1, TIGIT, TIM3, TIMP3, TLL1, TLR2, TLR3, TLX1, TLX3, TMEM173, TMEM38A, TMEM45B, TMEM55B, TMPRSS2, TNF, TNFRSF10C, TNFRSF11A, TNFRSF14, TNFRSF17, TNFRSF1A, TNFRSF1B, TNFRSF8, TNFRSF25, TNFRSF8, TNFRSF9, TNFSF10, TNFSF11, TNFSF12, TNFSF13B, TNFSF4, TNFSF9, TNKS, TNKS2, TNS1, TOP1, TOP2A, TP53, TP53BP1, TP53INP1, TP53INP2, TP63, TP73, TPM1, TPM2, TPM3, TPM4, TPSAB1, TPSB2, TPST1, TPX2, TRAT1, TREM2, TREX1, TRIM2, TRIM24, TRIM56, TRIP11, TROP2, TRPS1, TSC1, TSC2, TSHR, TTC39B, TTK, TTL, TTTY14, TTYH1, TWIST1, TYK2, TYMS, UBA7, UBE2C, UBE2T, UBXN4, UGT8, UNC5B, UPK1A, UPP1, USP44, USP6, USP8, VAV3, VCAM1, VCL, VEGFA, VEGFB, VEGFC, VGLL1, VHL, VIM, VNN3, VPREB1, VWF, WASH5P, WBSCR17, NSD2, NSD3, WIF1, WNT11, WNT16, WNT2, WNT5B, WNT7A, WNT7B, WNT8B, WT1, WWTR1, XCL1, XCL2, XIST, XPA, XPO1, YAP1, YWHAE, YY1, ZAP70, ZBP1, ZBTB16, ZBTB46, ZC3H13, ZC3HAV1, ZEB1, ZEB2, ZIC2, ZMAT3, ZMYM2, ZNF384, ZNF521, ZNF608, ZNF703, ZNF750, or ZNRF3.FMI Docket No.: 0255-WO / 0206-CD L&H Docket No.: F171-6038PCT 16. The method of any of clauses 13-15, wherein the predetermined panel includes one or more of: ALK, CD274, EGFR, ERBB2, MET, ROS1, TACSTD2, and wherein the condition includes non-small cell lung cancer (NSCLC).17. The method of any of clauses 13-16, wherein the predetermined panel includes one or more of: BRAF, ERBB2, MSH6, PMS2, MSH2, MLH1, and wherein the condition includes colorectal cancer (CRC).18. The method of any of clauses 13-17, wherein the predetermined panel includes one or more of: CLDN18, ERBB2, FGFR2b, and wherein the condition includes gastric cancer.19. The method of any of clauses 13-18, wherein the predetermined panel includes one or more of ESR1, PR, ERBB2, CD274, and wherein the condition includes breast cancer.20. The method of any of clauses 13-19, wherein the predetermined panel includes one or more of ERBB2, FOLR1, MSH6, PMS2, MSH2, MLH1, and wherein the condition includes endometrial cancer.21. The method of any of clauses 11-20, wherein the sequence read data indicates an RNA transcriptome of the first sample.22. The method of any of clauses 11-21, wherein the sequence read data indicates a whole exome of the first sample.23. The method of any of clauses 11-22, further including: receiving the first sample.24. The method of clause 23, wherein the first sample includes a tissue biopsy sample collected from the subject.25. The method of clause 23 or 24, wherein the first sample includes a liquid biopsy sample collected from the subject.26. The method of clause 25, wherein the first sample includes blood, plasma, cerebrospinal fluid, sputum, stool, urine, lymphatic fluid, or saliva.27. The method of any of clauses 11-26, further including: receiving the second sample.28. The method of clause 27, wherein the second sample includes a tissue biopsy sample collected from the subject.29. The method of any of clauses 11-28, wherein the first sample and the second sample include tumor cells and / or circulating tumor cells of the subject.30. The method of any of clauses 11-29, wherein the first sample and the second sample are collected from a tissue biopsy sample collected from a tumor of the subject.31. The method of any of clauses 11-30, wherein the condition includes cancer.32. The method of clause 31, wherein the cancer includes thyroid cancer, lung cancer, NSCLC, pancreatic cancer, prostate cancer, CRC, gastric cancer, breast cancer, or endometrial cancer.33. The method of clause 31 or 32, wherein the cancer is adrenal cancer, bladder cancer, blood cancer, bone cancer, brain cancer, breast cancer, carcinoma, cervical cancer, colon cancer, colorectal cancer, corpus uterine cancer, ear, nose and throat (ENT) cancer, endometrial cancer, esophageal cancer, gastrointestinal cancer, head and neck cancer, Hodgkin's disease, intestinal cancer, kidney cancer, larynx cancer, leukemia, liver cancer, lymph node cancer, lymphoma, lung cancer, melanoma, mesothelioma, myeloma, nasopharynx cancer, a neuroblastoma, non-Hodgkin'sFMI Docket No.: 0255-WO / 0206-CD L&H Docket No.: F171-6038PCT lymphoma, oral cancer, ovarian cancer, pancreatic cancer, penile cancer, pharynx cancer, prostate cancer, rectal cancer, sarcoma, seminoma, skin cancer, stomach cancer, a teratoma, testicular cancer, thyroid cancer, uterine cancer, vaginal cancer, a vascular tumor, or combinations or metastases thereof.34. The method of any of clauses 31-33, wherein the cancer is a B cell cancer (multiple myeloma), a melanoma, breast cancer, lung cancer, bronchus cancer, colorectal cancer, prostate cancer, pancreatic cancer, stomach cancer, ovarian cancer, urinary bladder cancer, brain cancer, central nervous system cancer, peripheral nervous system cancer, esophageal cancer, cervical cancer, uterine cancer, endometrial cancer, cancer of an oral cavity, cancer of a pharynx, liver cancer, kidney cancer, testicular cancer, biliary tract cancer, small bowel cancer, appendix cancer, salivary gland cancer, thyroid gland cancer, adrenal gland cancer, osteosarcoma, chondrosarcoma, a cancer of hematological tissue, an adenocarcinoma, an inflammatory myofibroblastic tumor, a gastrointestinal stromal tumor (GIST), colon cancer, multiple myeloma (MM), myelodysplastic syndrome (MDS), myeloproliferative disorder (MPD), acute lymphocytic leukemia (ALL), acute myelocytic leukemia (AML), chronic myelocytic leukemia (CML), chronic lymphocytic leukemia (CLL), polycythemia Vera, Hodgkin lymphoma, non-Hodgkin lymphoma (NHL), soft-tissue sarcoma, fibrosarcoma, myxosarcoma, liposarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms' tumor, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, meningioma, neuroblastoma, retinoblastoma, follicular lymphoma, diffuse large B-cell lymphoma, mantle cell lymphoma, hepatocellular carcinoma, thyroid cancer, gastric cancer, head and neck cancer, small cell cancer, essential thrombocythemia, agnogenic myeloid metaplasia, hypereosinophilic syndrome, systemic mastocytosis, familiar hypereosinophilia, chronic eosinophilic leukemia, neuroendocrine cancers, or a carcinoid tumor.35. The method of any of clauses 11-34, further including: providing a plurality of RNA molecules obtained from the first sample of the subject; generating a plurality of nucleic acid molecules by reverse transcribing the RNA molecules; ligating one or more adapters onto one or more nucleic acid molecules from the plurality of nucleic acid molecules; amplifying the one or more ligated nucleic acid molecules; capturing all or a subset of the amplified nucleic acid molecules; and sequencing, by a sequencer, the captured nucleic acid molecules to obtain a plurality of sequence reads that represent the captured nucleic acid molecules, thereby generating the sequence read data for the first samples. 36. The method of clause 35, wherein the plurality of nucleic acid molecules include RNA fragments, and wherein the sequence read data is indicative of at least one of: endpoint counts of the RNA fragments, lengths of the RNA fragments, read depth of the RNA fragments, or sequences of the RNA fragments.37. The method of clause 35 or 36, wherein the adapters include amplification primers, flow cell adapter sequences, substrate adapter sequences, or sample index sequences.FMI Docket No.: 0255-WO / 0206-CD L&H Docket No.: F171-6038PCT 38. The method of any of clauses 35-37, wherein the captured nucleic acid molecules are captured from the amplified nucleic acid molecules by hybridization to one or more bait molecules.39. The method of clause 38, wherein the one or more bait molecules include one or more additional nucleic acid molecules, each of the one or more additional nucleic acid molecules including a region that is complementary to a region of a captured nucleic acid molecule.40. The method of any of clauses 35-39, wherein amplifying the one or more ligated nucleic acid molecules includes performing a polymerase chain reaction (PCR) amplification technique, a non-PCR amplification technique, or an isothermal amplification technique.41. The method of any of clauses 35-40, wherein sequencing the captured nucleic acid molecules includes use of a massively parallel sequencing (MPS) technique, whole genome sequencing (WGS), whole exome sequencing, targeted sequencing, direct sequencing, or Sanger sequencing.42. The method of any of clauses 35-41, wherein sequencing the captured nucleic acid molecules includes nextgeneration sequencing (NGS).43. The method of any of clauses 35-42, wherein the sequencer includes a next-generation sequencer.44. The method of any of clauses 35-43, wherein sequencing the captured nucleic acid molecules includes sequencing-by-synthesis or nanopore sequencing.45. The method of any of clauses 35-44, wherein sequencing the captured nucleic acid molecules includes: generating, using the amplified ligated molecules, detection signals; detecting, by at least one sensor, the detection signals; and generating the sequence read data based on the detection signals.46. The method of clause 45, wherein the detection signals include electrical signals and / or optical signals.47. The method of clause 45 or 46, wherein generating, using the amplified ligated molecules, the detection signals includes: synthesizing, by a polymerase using fluorescently tagged nucleotide triphosphates (NTPs), a synthesized nucleic acid molecule that is complementary to one of the amplified ligated molecules, and wherein detecting, by the at least one sensor, the detection signals includes: detecting, by at least one optical sensor, optical signals emitted by the fluorescently tagged NTPs upon binding to the synthesized nucleic acid molecule, the optical signals being indicative of at least one sequence of the nucleic acid molecules of the first sample.48. The method of any of clauses 45-47, wherein generating, using the amplified ligated molecules, the detection signals includes: directing the amplified ligated molecules through a nanopore extending from a first space to a second space through a substrate, and wherein detecting, by the at least one sensor, the detection signals includes: detecting, by sensors disposed in the first space and the second space, an electrical signal over time, the electrical signal being indicative of at least one sequence of the nucleic acid molecules of the first sample.49. The method of any of clauses 11-48, wherein determining the RNA expression metrics of the plurality of genes includes: determining RNA expression of each gene of the plurality of genes; and comparing the RNA expression of each gene to a threshold.FMI Docket No.: 0255-WO / 0206-CD L&H Docket No.: F171-6038PCT 50. The method of clause 49, wherein the RNA expression metrics are indicative of a difference between the RNA expression of each gene and the threshold.51. The method of clause 49 or 50, wherein the threshold corresponds to the condition of the subject.52. The method of clause 51, wherein the condition includes cancer, and wherein the threshold corresponds to a type or a subtype of the cancer of the subject.53. The method of any of clauses 49-52, wherein the RNA expression of each gene includes one or more metrics.54. The method of any of clauses 49-53, wherein the RNA expression of the candidate gene is indicative of a number of RNA molecules corresponding to the candidate gene in the first sample.55. The method of clause 54, wherein the RNA expression of the candidate gene is indicative of a ratio of the number of RNA molecules corresponding to the candidate gene in the first sample to a number of RNA molecules in the first sample.56. The method of any of clauses 11-55, wherein identifying the candidate gene of the plurality of genes includes: comparing the RNA expression metrics of the plurality of genes.57. The method of any of clauses 11-56, wherein identifying the candidate gene of the plurality of genes is based on the RNA expression metrics of the candidate gene.58. The method of clause 57, the candidate gene being a first candidate gene, wherein identifying the candidate gene of the plurality of genes includes: determining that an RNA expression metric associated with the first candidate gene is greater than an RNA expression metric associated with a second candidate gene.59. The method of clause 57 or 58, the gene being a first candidate gene, wherein identifying the candidate gene of the plurality of genes includes: determining that an RNA expression metric associated with the first candidate gene is less than an RNA expression metric associated with a second candidate gene.60. The method of any of clauses 11-59, wherein identifying the candidate gene of the plurality of genes is based on the RNA expression metrics of a subset of the plurality of genes, the subset including the candidate gene.61. The method of any of clauses 11-60, further including: in response to identifying the candidate gene of the plurality of genes, outputting a recommendation to perform an immunohistochemistry (IHC) study of the candidate gene on the second sample of the subject.62. The method of any of clauses 11-61, further including: applying, to the second sample, a capture agent configured to bind to a protein associated with the candidate gene in the second sample; generating, using the capture agent, detection signals; and detecting, by at least one sensor, the detection signals, thereby generating the expression data indicative of the protein expression of the candidate gene in the second sample.63. The method of clause 62, wherein applying the capture agent includes: applying, to the second sample, a first antibody configured to bind to the protein associated with the candidate gene; and applying, to the second sample, a second antibody configured to bind to the first antibody, the second antibody being linked to an enzyme, and wherein generating the detection signals includes: applying, to the second sample, a substrate, the substrate being configured to convert to a detectable product using the enzyme.FMI Docket No.: 0255-WO / 0206-CD L&H Docket No.: F171-6038PCT 64. The method of clause 62 or 63, wherein applying the capture agent includes: applying, to the second sample, a first antibody configured to bind to the protein associated with the candidate gene and to an oligonucleotide, a protein, or a small molecule; and applying, to the second sample, a detectable label configured to bind to the oligonucleotide, the protein, or the small molecule, the detectable label including a fluorophore, a nanoparticle, or a colorimetric dye.65. The method of any of clauses 62-64, wherein the capture agent is linked to a detectable label, the detectable label including a fluorophore, a nanoparticle, or a colorimetric dye.66. The method of any of clauses 11-65, wherein predicting whether the therapy would be effective is based on the expression data and the sequence read data.67. The method of any of clauses 11-66, further including: determining clinicopathological features of the subject, wherein the predicting whether the therapy would be effective is based at least in part on the clinicopathological features of the subject.68. The method of clause 67, wherein the clinicopathological features include one or more of physical symptoms of the subject, medical history of the subject, family medical history of the subject, results of imaging tests performed on the subject, or results of laboratory tests performed on the subject.69. The method of any of clauses 11-68, further including: determining genomic data indicative of DNA in the first sample or the second sample, wherein the predicting is further based on the genomic data.70. The method of clause 69, wherein the genomic data includes results from at least one of: a whole transcriptome sequencing test; a targeted RNA sequencing test; a long-read RNA sequencing test; a comprehensive genomic profiling test; a whole genome sequencing (WGS) test; a whole exome sequencing (WES) test; a gene expression profiling test; a cancer hotspot panel test; a DNA methylation test; a DNA fragmentation test; or an RNA fragmentation test.71. The method of clause 69 or 70, wherein the genomic data includes results from a nucleic acid sequencingbased test.72. The method of any of clauses 11-71, further including: determining endpoint counts of DNA fragments and / or RNA fragments indicated by the sequence read data, wherein predicting whether the therapy would be effective is based at least in part on the endpoint counts of the DNA fragments and / or the RNA fragments indicated by the sequence read data.73. The method of any of clauses 11-72, further including: determining lengths of DNA fragments and / or RNA fragments indicated by the sequence read data, wherein predicting whether the therapy would be effective is based at least in part on the lengths of the DNA fragments and / or the RNA fragments.74. The method of any of clauses 11-73, further including: determining read depth of DNA fragments and / or RNA fragments, wherein predicting whether the therapy would be effective is based at least in part on the read depths of the DNA fragments and / or the RNA fragments.75. The method of any of clauses 11-74, further including: determining sequences of DNA fragments and / or RNA fragments, wherein predicting whether the therapy would be effective is based at least in part on the sequences of the DNA fragments and / or the RNA fragments.FMI Docket No.: 0255-WO / 0206-CD L&H Docket No.: F171-6038PCT 76. The method of any of clauses 11-75, wherein predicting whether the therapy would be effective includes: generating input features based on the expression data and one of more of: the sequence read data of the subject, clinicopathological features of the subject, or genomic data indicative of DNA in the first sample or the second sample; and determining, using a classifier, a likelihood that the therapy will be effective to treat the condition of the subject. 77. The method of clause 76, wherein generating the input features includes: inputting, into a machine learning (ML) model configured to detect the input features, the expression data and one of more of: the sequence read data of the subject, clinicopathological features of the subject, or genomic data indicative of DNA in the first sample or the second sample.78. The method of clause 77, wherein the machine learning model includes a logistic regression model, a random forest model, an artificial neural network (ANN), a decision tree, a k-nearest neighbor (KNN) model, a support vector machine (SVM), or a naive Bayes classifier.79. The method of clause 77 or 78, wherein the input features are determined based at least in part on preclassified data, the pre-classified data being generated by: identifying training sequence read data associated with samples corresponding to a plurality of individuals omitting the subject; and generating the pre-classified data by labeling the training data with labels indicative of treatment conditions of the plurality of subjects, the treatment conditions being indicative of whether the therapy effectively treated conditions of the plurality of the subjects.80. The method of clause 79, further including: training the ML model to identify attributes, indicated by the training data, that are predictive of the treatment conditions of the plurality of subjects, wherein the input features are instances of the attributes identified via the training of the ML model.81. The method of clause 79 or 80, wherein the pre-classified data is based on a sample obtained from an individual having a cancer that was effectively treated by the therapy.82. The method of any of clauses 79-81, wherein the pre-classified data is based on a sample obtained from an individual having a cancer that was not effectively treated by the therapy.83. The method of any of clauses 76-82, wherein the classifier is a ML-based classifier.84. The method of clause 83, further including: training the ML-based classifier using training data, the training data including population features of population samples obtained from a population omitting the subject.85. The method of clause 84, wherein training the ML-based classifier using the training data includes performing supervised learning on the ML-based classifier.86. The method of clause 84 or 85, wherein training the ML-based classifier using the training data includes performing unsupervised learning on the ML-based classifier.87. The method of any of clauses 84-86, wherein training the ML-based classifier using the training data includes optimizing parameters of the ML-based classifier using the training data.88. The method of any of clauses 83-87, wherein the ML-based classifier includes at least one of a: an artificial neural network (ANN); a logistic regression model; a random forest model; a decision tree; a k-nearest neighbor (KNN) model; a support vector machine (SVM); or a naive Bayes classifier.FMI Docket No.: 0255-WO / 0206-CD L&H Docket No.: F171-6038PCT 89. The method of any of clauses 11-88, wherein the therapy includes an antibody-drug conjugate, an immune checkpoint inhibitor, a T-cell receptor (TCR) therapy, a TCR-bispecific molecule, a personalized cancer vaccine, a targeted therapy, a personalized therapy, or a precision medicine therapy.90. The method of any of clauses 11-89, wherein the therapy includes at least one of chemotherapy, radiation therapy, an immunotherapy a targeted therapy, or surgery.91. The method of any of clauses 11-90, wherein the therapy includes a dosage of one or more therapeutic agents predicted to treat the condition of the subject.92. The method of any of clauses 11-91, the therapy being a first therapy, wherein predicting whether the first therapy would be effective includes: determining, based at least in part on the expression data, that the first therapy would not effectively treat the condition of the subject; and selecting, based at least in part on the expression data, a second therapy predicted to effectively treat the condition of the subject.93. The method of any of clauses 11-92, further including: determining, based at least in part on the expression data, that the therapy would effectively treat the condition of the subject.94. The method of clause 93, further including: administering, based on determining whether the therapy would effectively treat the condition of the subject, the therapy to the subject.95. The method of any of clauses 11-94, further including: determining, based at least in part on the sequence read data and / or the expression data, at least one of: a cancer type of the subject; a cancer subtype of the subject; a metastasis profile of the subject; a predicted survivability of the subject; a predicted symptom of the subject; a predicted effective therapy to treat the cancer of the subject; a predicted resistance of the subject to a treatment of the cancer; a general health of the subject; a genomic age of the subject; a predicted stage of the cancer of the subject; a predicted grade of the cancer of the subject; or a predicted Eastern Cooperative Oncology Group (ECOG) performance status of the subject.96. The method of any of clauses 11-95, further including: determining, based at least in part on the sequence read data and / or the expression data, a health metric and / or a disease metric of the subject.97. The method of any of clauses 11-96, further including: determining, based at least in part on the sequence read data and / or the expression data, a genomic subtype and / or a phenotypic subtype of the condition of the subject.98. The method of any of clauses 11-97, further including: generating a report indicating whether the therapy would effectively treat the condition of the subject; and outputting the report.99. The method of clause 98, wherein the report further indicates the sequence read data and / or the expression data.100. The method of clause 98 or 99, wherein outputting the report includes: transmitting data indicating the report to an external device.101. The method of clause 100, wherein the external device is associated with the subject and / or a healthcare provider.102. The method of clause 100 or 101, wherein the data is transmitted over one or more communication networks.FMI Docket No.: 0255-WO / 0206-CD L&H Docket No.: F171-6038PCT 103. The method of any of clauses 100-102, wherein the data is transmitted over a peer-to-peer connection.104. The method of any of clauses 98-103, wherein outputting the report includes: visually presenting, by a display, the report.105. The method of any of clauses 11-104, further including: determining, based on the sequence read data and / or the expression data, whether the subject is eligible for a clinical trial.106. A system, including: at least one processor; and memory storing instructions that, when executed by the at least one processor, cause the at least one processor to perform operations including: identifying sequence read data representing RNA in a first sample of a subject; determining RNA expression metrics of a plurality of genes; identifying, based on the RNA expression metrics of the plurality of genes, a candidate gene of the plurality of genes; receiving, based on identifying the candidate gene, expression data indicative of protein expression of the gene in a second sample of a subject; and predicting, based on the expression data, whether a therapy would be effective at treating a condition of the subject.107. The system of clause 106, further including: a sequencer configured to generate the sequence read data by sequencing a plurality of nucleic acid molecules in the first sample.108. The system of clause 106 or 107, further including: a transceiver configured to transmit data indicating whether the therapy would effectively treat the condition of the subject.109. The system of any of clauses 106-108, further including: an output device configured to output an indication of whether the therapy would effectively treat the condition of the subject.110. A non-transitory computer readable medium storing instructions for performing operations including: identifying sequence read data representing RNA in a first sample of a subject; determining RNA expression metrics of a plurality of genes; identifying, based on the RNA expression metrics of the plurality of genes, a candidate gene of the plurality of genes; receiving, based on identifying the candidate gene, expression data indicative of protein expression of the candidate gene in a second sample of a subject; and predicting, based on the expression data, whether a therapy would be effective at treating a condition of the subject.111. A method of identifying an individual having a condition and predicted to respond to a therapy to treat the condition, the method including detecting in a sample from the individual: a first predetermined pattern of RNA expression of one or more genes and a second predetermined pattern of protein expression of a candidate gene of the one or more genes in a sample of the individual, wherein detection of the first predetermined pattern and the second predetermined pattern identifies the individual as one who may respond to the therapy.112. A method of treating or delaying progression of a condition in an individual in need thereof, including: acquiring knowledge of: RNA expression of multiple genes in a sample of the individual; selecting a candidate gene of the multiple genes based on the RNA expression of the multiple genes in the sample; acquiring knowledge of: protein expression of the candidate gene in the sample of the individual; selecting a treatment based on the protein expression of the candidate gene; and administering to the individual an effective amount of the treatment.FMI Docket No.: 0255-WO / 0206-CD L&H Docket No.: F171-6038PCT 113. A method including: identifying sequence read data representing RNA in a sample obtained from a subject; determining, based on the sequence read data, RNA expression metrics of a plurality of genes; and determining, based on the RNA expression metrics of the plurality of genes, whether to identify expression data indicative of protein expression of a particular gene.114. The method of clause 113, wherein the sample includes a liquid biopsy sample.115. The method of clause 113 or 114, wherein determining whether to identify expression data includes: determining whether to obtain a tissue biopsy sample from the subject.116. The method of any of clauses 113-115, wherein determining whether to identify expression data includes: predicting, based on the sequence read data, that a therapy would not effectively treat a cancer of the subject.117. The method of any of clauses 113-116, wherein determining whether to identify expression data includes: predicting, based on the sequence read data, that a therapy would effectively treat a cancer of the subject.Conclusion
[0165] All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference in their entirety to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference in its entirety. In the event of a conflict between a term herein and a term in an incorporated reference, the term herein controls.
[0166] The features disclosed in the foregoing description, or the following claims, or the accompanying drawings, expressed in their specific forms or in terms of a means for performing the disclosed function, or a method or process for attaining the disclosed result, as appropriate, may, separately, or in any combination of such features, be used for realizing implementations of the disclosure in diverse forms thereof.
[0167] As will be understood by one of ordinary skill in the art, each implementation disclosed herein can comprise, consist essentially of or consist of its particular stated element, step, or component. Thus, the terms “include” or “including” should be interpreted to recite: “comprise, consist of, or consist essentially of.” The transition term “comprise” or “comprises" means has, but is not limited to, and allows for the inclusion of unspecified elements, steps, ingredients, or components, even in major amounts. The transitional phrase “consisting of” excludes any element, step, ingredient or component not specified. The transition phrase “consisting essentially of’ limits the scope of the implementation to the specified elements, steps, ingredients or components and to those that do not materially affect the implementation. As used herein, the term “based on” is equivalent to “based at least partly on,” unless otherwise specified.
[0168] Unless otherwise indicated, all numbers expressing quantities, properties, conditions, and so forth used in the specification and claims are to be understood as being modified in all instances by the term “about.” Accordingly, unless indicated to the contrary, the numerical parameters set forth in the specification and attached claims are approximations that may vary depending upon the desired properties sought to be obtained by the present disclosure. At the very least, and not as an attempt to limit the application of the doctrine of equivalents to the scope of the claims, each numerical parameter should at least be construed in light of the number of reported significant digits and by applying ordinary rounding techniques. When further clarity is required, the term “about” has the meaning reasonably ascribed to it by a person skilledFMI Docket No.: 0255-WO / 0206-CD L&H Docket No.: F171-6038PCT in the art when used in conjunction with a stated numerical value or range, i.e., denoting somewhat more or somewhat less than the stated value or range, to within a range of ±20% of the stated value; ±19% of the stated value; ±18% of the stated value; ±17% of the stated value; ±16% of the stated value; ±15% of the stated value; ±14% of the stated value; ±13% of the stated value; ±12% of the stated value; ±11% of the stated value; ±10% of the stated value; ±9% of the stated value; ±8% of the stated value; ±7% of the stated value; ±6% of the stated value; ±5% of the stated value; ±4% of the stated value; ±3% of the stated value; ±2% of the stated value; or ±1% of the stated value.
[0169] Notwithstanding that the numerical ranges and parameters setting forth the broad scope of the disclosure are approximations, the numerical values set forth in the specific examples are reported as precisely as possible. Any numerical value, however, inherently contains certain errors necessarily resulting from the standard deviation found in their respective testing measurements.
[0170] The terms “a,” “an,” “the,” and similar referents used in the context of describing implementations (especially in the context of the following claims) are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context. Recitation of ranges of values herein is merely intended to serve as a shorthand method of referring individually to each separate value falling within the range. Unless otherwise indicated herein, each individual value is incorporated into the specification as if it were individually recited herein. All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (e.g., “such as") provided herein is intended merely to better illuminate implementations of the disclosure and does not pose a limitation on the scope of the disclosure. No language in the specification should be construed as indicating any non-claimed element essential to the practice of implementations of the disclosure.
[0171] Groupings of alternative elements or implementations disclosed herein are not to be construed as limitations. Each group member may be referred to and claimed individually or in any combination with other members of the group or other elements found herein. It is anticipated that one or more members of a group may be included in, or deleted from, a group for reasons of convenience and / or patentability. When any such inclusion or deletion occurs, the specification is deemed to contain the group as modified thus fulfilling the written description of all Markush groups used in the appended claims.
[0172] Unless otherwise indicated, the practice of the present disclosure can employ conventional techniques of immunology, molecular biology, microbiology, cell biology and recombinant DNA. These methods are described in the following publications. See, e.g., Sambrook, et al. Molecular Cloning: A Laboratory Manual, 2nd Edition (1989); F. M. Ausubel, et al. eds., Current Protocols in Molecular Biology, (1987); the series Methods IN Enzymology (Academic Press, Inc.); M. MacPherson, et al., PCR: A Practical Approach, IRL Press at Oxford University Press (1991); MacPherson et al., eds. PCR 2: Practical Approach, (1995); Harlow and Lane, eds. Antibodies, A Laboratory Manual, (1988); and R. I. Freshney, ed. Animal Cell Culture (1987).
[0173] Tumor mutational burden (TMB) is a measure of the number of mutations carried by tumor cells. By comparing DNA sequences from a patient's healthy tissues and tumor cells, the number of acquired somatic mutations present inFMI Docket No.: 0255-WO / 0206-CD L&H Docket No.: F171-6038PCT tumors, but not in normal tissues, may be determined. In some instances, driver mutations may be excluded from a TMB calculation.
[0174] In certain examples, "tumor mutational burden" or “TMB” refers to the number of somatic mutations in a tumor's genome and / or the number of somatic mutations per area of the tumor's genome. In some embodiments, TMB, as used herein, refers to the number of somatic mutations per megabase (Mb) of DNA sequenced. In some embodiments, germline (inherited) variants are excluded when determining TMB, given that the immune system has a higher likelihood of recognizing these as self. In various cases, driver mutations are excluded from a TMB calculation.
[0175] Microsatellites are highly polymorphic DNA-repeat regions. In certain examples, ''microsatellite” refers to a repetitive nucleic acid having repeat units of less than about 10 base pairs or nucleotides in length. In certain examples, a microsatellite refers to a tract of tandemly repeated (i.e. adjacent) DNA motifs ranging from one to six or up to ten nucleotides, with each motif repeated 5 to 50 repeated times. “Microsatellite instability” refers to genetic instability in the microsatellite regions. Cancer patients with microsatellite instability classified as being high (MSI-H or MSI-High) frequently exhibit an accumulation of somatic mutations in tumor cells that leads to a range of molecular and biological changes including high tumor mutational burden, increased expression of neoantigens and abundant tumor-infiltrating lymphocytes. Chang et al. ''Microsatellite Instability: A Predictive Biomarker for Cancer Immunotherapy,” Appl Immunohistochem Mol Morphol, 26(2):e15-e21 (2018). These changes have been linked to increased sensitivity to checkpoint inhibitor drugs, such as pembrolizumab, which is used to treat advanced melanoma, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and classical Hodgkin lymphoma.
[0176] A viral status test refers to a test that identifies the presence of viral RNA or DNA in a subject. The test can identify viral load and / or viral identity. For example, the viral status test can identify the presence of viral RNA or DNA associated with the occurrence of certain cancers. Examples of such viruses include Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV), Kaposi Sarcoma-Associated Herpesvirus (KSHV), Merkel Cell Polyomavirus (MCV), Human Papillomavirus (HPV), Human immunodeficiency Virus Type 1 (HIV-1, or HIV), Human T-Cell Lymphotropic Virus Type 1 (HTLV-1), and Epstein- Barr Virus (EBV).
[0177] Cancer “hotspot” mutations give rise to oncological outcomes. PhyloP, SIFT, Grantham, COSMIC and PolyPhen-2 are in silico tools that can be used to assess pathogenicity of identified variants. Exemplary hotspot genes and mutations include EGFR exon 19 activating mutation, EGFR exon 19 deletion, EGFR exon 19 insertion, EGFR exon 19 sensitizing mutation, EGFR exon 20 activation mutation, EGFR exon 20 insertion, EGFR G719 mutation, EGFR L858R mutation, EGFR L861 mutation, EGFR S768 mutation, EGFR T790M mutation, C797 mutation, KIT activating mutation, KRAS activating mutation, MET activating mutation, NRAS activating mutation, PMS2 promoter mutations, among many others. Hotspot mutations also occur in the following genes: AKT2, BRCA1, BRCA2, ERC1, NSD1, POLH, PPM1G, PTEN, RAD18, RAD51, RAD51B, RB1, TERT, TP53, TP53Bp1, ALK, ARMT1, ATAD5, ATG7, ATIC, AXL, BIRC6, BRD3, BRD4, CAPRIN1, CCAR2, CCDC6, CDK5RAP2, CHD9, CIT, CTNNB1, CUL1, EBF1, EIF3E, HIP1, HMGA2, IRF2BP2, NOTCH1, NOTCH4, NPM1, OFD1, TACC1, TACC3, TERF2, TMEM106B, UBE2L3, USP10, WRDR48, YAP1, ZEB2, and ZMYND8.FMI Docket No.: 0255-WO / 0206-CD L&H Docket No.: F171-6038PCT
[0178] A “DNA methylation test" refers to an assay, which can be commercially available, for distinguishing methylated versus unmethylated cytosine loci in DNA. Techniques for measuring cytosine methylation include bisulfite-based methylation assays. The addition of bisulfite to DNA results in the methylation of unmethylated cytosine and its ultimate conversion to the nucleotide uracil. Uracil has similar binding properties to thiamine in the DNA sequence. Previously methylated cytosine does not undergo similar chemical conversion on exposure to bisulfite. Bisulfite assays can thus be used to discriminate previously methylated versus unmethylated cytosine.
[0179] An exemplary quantitative methylation detection assay combines bisulfite treatment and restriction analysis COBRA, which uses methylation sensitive restriction endonucleases, gel electrophoresis, and detection based on labeled hybridization probes. (Ziong and Laird, Nucleic Acid Res. 1997 25; 2532-4) Another exemplary detection assay is the methylation specific polymerase chain reaction PCR (MSPCR) for amplification of DNA segments of interest. This assay can be performed after sodium bisulfite conversion of cytosine and uses methylation sensitive probes. Other detection assays include the Quantitative Methylation (QM) assay, which combines PCR amplification with fluorescent probes designed to bind to putative methylation sites; MethyLight™ (Qiagen, Redwood City, CA) a quantitative methylation detection assay that uses fluorescence-based PCR (Eads, et al., Cancer Res. 1999; 59:2302-2306); and Ms-SNuPE, a quantitative technique for determining differences in methylation levels in CpG sites. As with other techniques, Ms-SNuPE also requires bisulfite treatment to be performed first, leading to the conversion of unmethylated cytosine to uracil while methyl cytosine is unaffected. PCR primers specific for bisulfite converted DNA are then used to amplify the target sequence of interest. The amplified PCR product is isolated and used to quantitate the methylation status of the CpG site of interest. (Gonzalgo and Jones Nuclei Acids Res1997; 25:252-31).
[0180] In particular embodiments, pyrosequencing can be used to detect marker methylation. Pyrosequencing is a method of DNA sequencing that relies on detection of the release of pyrophosphates as DNA is synthesized (and is therefore a "sequencing by synthesis” technique). To assess methylation by pyrosequencing, a DNA sample can be incubated with sodium bisulfite, converting unmethylated cytosine to uracil. The presence of uracil will result in thymine incorporation during PCR amplification. Therefore, sequencing results that include thymine at a nucleotide position that is known to encode cytosine can be interpreted as unmethylated sites. In contrast cytosines present in the sequencing results indicate that the site was methylated in the original DNA sample, because methylation protects cytosine from conversion to uracil upon treatment. Bisulfite treatment can also be performed on control samples with known methylation patterns, to reduce or eliminate false positive results. Commercially available pyrosequencing machines include Pyro Mark Q96 (Qiagen, Hilden, Germany). For more details on methods to use pyrosequencing for measurement of methylation, see Delaney et al. Methods Mol Biol. 20151343: 249-264. Pyrosequencing is especially useful for detecting methylation in the CpG sites within genes.
[0181] In particular embodiments, a protein marker is detected by contacting a sample with reagents (e.g., antibodies), generating complexes of reagent and marker(s), and detecting the complexes. Particular embodiments for detecting and measuring protein levels can use methods including agglutination, chemiluminescence, electro-chemiluminescence (ECL), enzyme-linked immunoassays (ELISA), immunoassay, immunoblotting, immunodiffusion, immunoelectrophoresis,FMI Docket No.: 0255-WO / 0206-CD L&H Docket No.: F171-6038PCT immunofluorescence, immunohistochemistry, immunoprecipitation, mass-spectrometry, and western blot. See also, e.g., E. Maggio, Enzyme-Immunoassay (1980), CRC Press, Inc., Boca Raton, Fla; and U.S. Pat. Nos. 4,727,022; 4,659,678; 4,376,110; 4,275,149; 4,233,402; and 4,230,797.
[0182] Read depth refers to the number of times that a specific genomic site is sequenced during a sequencing run.
[0183] Certain implementations are described herein, including the best mode known to the inventors for carrying out implementations of the disclosure. Of course, variations on these described implementations will become apparent to those of ordinary skill in the art upon reading the foregoing description. The inventor expects skilled artisans to employ such variations as appropriate, and the inventors intend for implementations to be practiced otherwise than specifically described herein. Accordingly, the scope of this disclosure includes all modifications and equivalents of the subject matter recited in the claims appended hereto as permitted by applicable law. Moreover, any combination of the above-described elements in all possible variations thereof is encompassed by implementations of the disclosure unless otherwise indicated herein or otherwise clearly contradicted by context.
Claims
FMI Docket No.: 0255-WO / 0206-CD L&H Docket No.: F171-6038PCT CLAIMSWhat is claimed is:
1. A method comprising:receiving, at one or more processors, sequence read data representing RNA in a first sample of a subject having a condition;determining, by the one or more processors, RNA expression metrics of a plurality of genes;identifying, by the one or more processors and based on the RNA expression metrics of the plurality of genes, a candidate gene of the plurality of genes; andin response to identifying the candidate gene of the plurality of genes, outputting, by the one or more processors, a recommendation to perform an immunohistochemistry (IHC) study of the candidate gene on a second sample of the subject.
2. The method of claim 1 , wherein the sequence read data indicates a predetermined panel of genes of the first sample, the predetermined panel comprising the candidate gene, and / orwherein the first sample and the second sample comprise tumor cells and / or circulating tumor cells of the subject.
3. The method of claim 2, wherein the predetermined panel comprises one or more of: ALK, CD274, EGFR, ERBB2, MET, ROS1, TACSTD2, and wherein the condition comprises non-small cell lung cancer (NSCLC), wherein the predetermined panel comprises one or more of: BRAF, ERBB2, MSH6, PMS2, MSH2, MLH1, and wherein the condition comprises colorectal cancer (CRC),wherein the predetermined panel comprises one or more of: CLDN18, ERBB2, FGFR2b, and wherein the condition comprises gastric cancer,wherein the predetermined panel comprises one or more of ESR1, PR, ERBB2, CD274, and wherein the condition comprises breast cancer, orwherein the predetermined panel comprises one or more of ERBB2, FOLR1, MSH6, PMS2, MSH2, MLH1, and wherein the condition comprises endometrial cancer.
4. The method of claim 1 , wherein the first sample comprises a tissue biopsy sample or a liquid biopsy sample collected from the subject, and / orwherein the second sample comprises a tissue biopsy sample collected from the subject.
5. The method of claim 1 , wherein the first sample of the subject comprises RNA fragments, andwherein the sequence read data is indicative of at least one of: endpoint counts of the RNA fragments, lengths of the RNA fragments, read depth of the RNA fragments, or sequences of the RNA fragments.
6. The method of claim 1 , wherein determining the RNA expression metrics of the plurality of genes comprises:determining RNA expression of each gene of the plurality of genes; andcomparing the RNA expression of each gene to a threshold.FMI Docket No.: 0255-WO / 0206-CD L&H Docket No.: F171-6038PCT 7. The method of claim 6, wherein the threshold corresponds to the condition of the subject, and / or wherein the RNA expression of the candidate gene is indicative of a number of RNA molecules corresponding to the candidate gene in the first sample.
8. The method of claim 1 , further comprising:in response to outputting the recommendation to perform the IHC study of the candidate gene on the second sample of the subject, receiving, at the one or more processors, expression data indicative of protein expression of the candidate gene in the second sample of the subject; andpredicting, by the processor and based at least in part on the expression data, whether a therapy would be effective at treating a condition of the subject.
9. The method of claim 8, further comprising:determining clinicopathological features of the subject, wherein the predicting whether the therapy would be effective is based at least in part on the clinicopathological features of the subject, the clinicopathological features comprising one or more of:physical symptoms of the subject, medical history of the subject, family medical history of the subject, results of imaging tests performed on the subject, or results of laboratory tests performed on the subject.
10. The method of claim 8, further comprising:determining endpoint counts of DNA fragments and / or RNA fragments indicated by the sequence read data, wherein predicting whether the therapy would be effective is based at least in part on the endpoint counts of the DNA fragments and / or the RNA fragments indicated by the sequence read data;determining lengths of DNA fragments and / or RNA fragments indicated by the sequence read data, wherein predicting whether the therapy would be effective is based at least in part on the lengths of the DNA fragments and / or the RNA fragments;determining read depth of DNA fragments and / or RNA fragments, wherein predicting whether the therapy would be effective is based at least in part on the read depths of the DNA fragments and / or the RNA fragments; or determining sequences of DNA fragments and / or RNA fragments, wherein predicting whether the therapy would be effective is based at least in part on the sequences of the DNA fragments and / or the RNA fragments.
11. The method of claim 8, wherein predicting whether the therapy would be effective comprises:generating input features based on the expression data and one of more of: the sequence read data of the subject, clinicopathological features of the subject, or genomic data indicative of DNA in the first sample or the second sample; anddetermining, using a classifier, a likelihood that the therapy will be effective to treat the condition of the subject.
12. The method of claim 11, wherein generating the input features comprises:inputting, into a machine learning (ML) model configured to detect the input features, the expression data and one of more of: the sequence read data of the subject, clinicopathological features of the subject, or genomic data indicative of DNA in the first sample or the second sample.FMI Docket No.: 0255-WO / 0206-CD L&H Docket No.: F171-6038PCT 13. The method of claim 8, wherein the therapy comprises an antibody-drug conjugate, an immune checkpoint inhibitor, a T-cell receptor (TCR) therapy, a TCR-bispecific molecule, a personalized cancer vaccine, a targeted therapy, a personalized therapy, or a precision medicine therapy.
14. The method of claim 8, the therapy being a first therapy, wherein predicting whether the first therapy would be effective comprises:determining, based at least in part on the expression data, that the first therapy would not effectively treat the condition of the subject; andselecting, based at least in part on the expression data, a second therapy predicted to effectively treat the condition of the subject.
15. The method of claim 8, further comprising:generating a report indicating whether the therapy would effectively treat the condition of the subject; and outputting the report.
16. A system, comprising:at least one processor; andmemory storing instructions that, when executed by the at least one processor, cause the at least one processor to perform operations comprising:identifying sequence read data representing RNA in a first sample of a subject;determining RNA expression metrics of a plurality of genes;identifying, based on the RNA expression metrics of the plurality of genes, a candidate gene of the plurality of genes; andin response to identifying the candidate gene of the plurality of genes, outputting a recommendation to perform an IHC study of the candidate gene on a second sample of the subject.
17. The system of claim 16, wherein the operations further comprise:receiving, based on identifying the candidate gene, expression data indicative of protein expression of the gene in the second sample of the subject; andpredicting, based on the expression data, whether a therapy would be effective at treating a condition of the subject18. A method comprising:providing a plurality of RNA molecules obtained from a first tissue sample from a tumor of a subject; generating a plurality of nucleic acid molecules by reverse transcribing the RNA molecules;ligating one or more adapters onto one or more nucleic acid molecules from the plurality of nucleic acid molecules;amplifying the one or more ligated nucleic acid molecules from the plurality of nucleic acid molecules; capturing amplified nucleic acid molecules from the amplified nucleic acid molecules;FMI Docket No.: 0255-WO / 0206-CD L&H Docket No.: F171-6038PCT sequencing, by a sequencer, all or a subset of the captured amplified nucleic acid molecules to obtain a plurality of sequence reads that represent the sequenced amplified nucleic acid molecules thereby generating sequence read data;receiving, at one or more processors, the sequence read data for the plurality of sequence reads; determining, by the one or more processors and based on the sequence read data, RNA expression of multiple genes in the first tissue sample;identifying an expressed gene of the multiple genes by comparing the RNA expression of the multiple genes in the first tissue sample to predetermined thresholds;outputting, by the one or more processors, a recommendation to perform an IHC study of the expressed gene on a second tissue sample of the tumor of the subject;receiving, at the one or more processors, expression data indicative of protein expression of the expressed gene in the second tissue sample; andpredicting that a therapy will be effective to treat the tumor of the subject based at least in part on the expression data.
19. The method of claim 18, further comprising:receiving a tissue biopsy sample from the tumor of the subject; andcollecting, from the tissue biopsy sample, the first tissue sample and the second tissue sample.
20. The method of claim 18, wherein predicting that the therapy will be effective to treat the tumor of the subject is based on the expression data and the sequence read data.
